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ABSTRACT
A STATIN-REGULATED MICRORNA REPRESSES C-MYC EXPRESSION AND

FUNCTION
APANA AGHA L. TAKWI
NOVEMBER 1, 2011
c-Myc dysregulation is one of the most common abnormalities found in human cancer.
MicroRNAs (miRNAs) are functionally intertwined with the c-Myc network as multiple
miRNAs are regulated by c-Myc, while others directly suppress c-Myc expression. In
this work, we identified miR-33b as a primate-specific negative regulator of c-Myc. The
human miR-33b gene is located at 17pl1.2, a genomic locus frequently lost in
medulloblastomas, which are pediatric brain tumors that display c-Myc overproduction.
Through a small-scale screening with drugs approved by the US Food and Drug
Administration (FDA), we found that lovastatin up-regulated miR-33b expression,
reduced cell proliferation, and impaired c-Myc expression and function in miR-33bpositive medulloblastoma cells. In addition, a low dose oflovastatin treatment at a level
comparable to approved human oral use reduced tumor growth in mice orthotopically
xenografted with cells carrying miR-33b, but not with cells lacking miR-33b. This work
presents a highly promising therapeutic option, using drug repurposing and a miRNA as a
biomarker, against cancers that over-express c-Myc.
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CHAPTER 1
MICRORNA REGULATION AND MEDULLOBLASTOMA DEVELOPMENT
1.1. INTRODUCTION
The most common pediatric malignancies are leukemia/lymphoma (40%) and primary
central nervous system (CNS) tumors (30%). There are very few genetic changes
identified in childhood malignancies e.g. fewer p53 mutations. These changes often arise
in embryonal precursor cells where aberrant signaling in normal development (1).
Despite advances in recent years that have resulted in an improvement in the survival rate
of childhood cancers (80%), these cancers still remain the most common cause of
childhood death due to disease in western countries (2).

1.2. CHILDHOOD BRAIN TUMORS
Collectively, tumors of the brain are the most common solid tumors and most chemoresistant neoplasms of childhood and adolescence. Malignant tumors of the brain account
for 21 % of all cancers and 24% of all cancer-related deaths in this age group. They
account for 4.3 cases per 100,000 people yearly in the U.S. and are among the leading
causes of cancer-related morbidity and mortality during childhood (3, 4). CNS tumors
show diverse histologies, location and survival. Treatment regiments for brain tumors
involve surgery, radiation and chemotherapy. Complications as a result of treatment are
of significant concern, as long term side effects are common in surviving patients (5).
Tumors of the CNS are classified based on the World Health Organization (WHO)
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classification system of biological behavior of tumors, which includes a grading scale
corresponding to aggressiveness (6). The malignancy scale is crucial for determining
adequate therapies. In children these grades are from Grade I to Grade IV, where Grade.!
applies to lesions that have low proliferative potential and that are often correlated with
good prognosis. Grade IV applies to high-proliferative, mitotically active cells and is
often associated with fatal outcomes (6). A further sub-division exists whereby tumors
are grouped based on the site of origin and type of cells. The most common childhood
CNS tumors are located in the posterior fossa: astrocytoma (44%), medulloblastoma
(19%) and ependynoma (10%) (7).

1.2.1. Treatment

Standard therapy for brain tumors consists of surgery followed by radiation to the entire
craniospinal axis with boosts to both the primary tumor site and focal CNS metastatic
sites. Following diagnosis, location and histology (type and grade) of the tumor
determine if the tumor is surgically accessible. Improved techniques such as functional
imaging and diffusion tensor imaging help the surgeon map the brain and define tracts
and connections, leading to better tumor resection management and less harm to normal
tissues (8). Low grade glioma is completely resected and no further treatment is needed.
Medulloblastoma and ependymoma, on the other hand, are often only partially resected
through surgery. In such cases radiation and chemotherapy are necessary after surgery
(9).

The most common radiation technique is craniospinal radiotherapy (CSRT). Patients
treated with CSRT receive radiation to the craniospinal axis with an additional boost to
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the tumor. Novel radiation techniques are available and are in clinical trials including
conformal radiation therapy (CRT) that incorporates three-dimensional CT and MRI
imaging, allowing more precise planning and delivery, which helps to identify the tumor
and surrounding critical structures.

A variety of chemotherapeutic agents are effective against CNS tumors, including
platinum compounds, nitrosureas, cyclophosphamide, iphosphamide, temozolomide,
etoposide and vincristine. Children who have undergone both chemotherapy and
radiation therapy have a significantly higher survival rate. Chemotherapy eligibility
depends on the type and stage of tumor, and age of the patient. In children younger than
3years with unresectable tumors, chemotherapy is used to delay radiation therapy or, at
best, reduce the dose while trying to maintain high cure rates. Combinatorial
chemotherapy is considered most effective when used with surgery and radiation
treatment to control local and disseminated disease (9).

1.2.2. Late Effects
Late effects are likely the result of the complex interactions between the tumor, different
treatment modalities and individual characteristics in a growing and developing child (7).
Patients receiving radiation therapy are at risk of developing side effects that negatively
affect cognitive, endocrine and neurological functions (5). Radiation has been reported to
cause neuro-endocrine abnormalities, personality changes and neuro-cognitive sequelae
for surviving children (5). Reduced IQ has been reported for children receiving whole
brain radiation (10, 11); while endocrine sequelae depend on dose of radiation and age of
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the patient. Patients receiving as low as 16 gray (Gy) acquire damage to the
hypothalamic-pituitary axis with abnormalities in production of growth hormones (12).
Patients receiving higher doses, >40gy, develop endocrine and reproductive dysfunction
(e.g. decreased production of thyroid and follicle stimulating hormones,
adrenocorticotrophic hormone, and luteinizing hormone) (12).

1.3. MEDULLOBLASTOMA
Medulloblastoma is the second most frequent brain tumor in children after pilocytic
astrocytoma. Most medulloblastomas occur in the first decade of life (13, 14).
Medulloblastoma is an embryonal tumor of the brain, analogous to Wilms tumor of the
kidney and adrenal neuroblastoma (15). Its embryonal nature is underlined by its high
incidence in infants and children and by its undifferentiated, immature appearance, which
resembles developing neural tissue (15). It is a densely cellular, midline cerebellar tumor
that arises over the roof of the fourth ventricle (15). Despite debates over its origin and
nomenclature, medulloblastoma is grouped under the name primitive neuroectodermal
tumors (PNET) because it was thOUght historically that all embryonic tumors originated
from a common precursor cell of the subependymal matrix in the eNS (15). Gene
profiling technologies have demonstrated that embryonic brain tumors are a
heterogeneous group of neoplasms and that these tumors should be classified based on
tumor location, histology and patterns of differentiation (16). Increasing evidence suggest
that medulloblastoma may originate from precursor cells (e.g. granule cells) in the
external granular layer (EGL) of the cerebellum (16, 17). The development of
medulloblastoma follows a specific sequence of events [(18), Fig. 1]. The less aggressive
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classic and desmoplastic medulloblastoma subtypes generally arise upon constitutive
activation of wingless (Wnt) or sonic hedgehog (Shh) signaling. Subsequent activation of
MYC, through gene amplification or over-expression, coupled with chromosome 17p loss
gives rise to the more aggressive, metastatic large cell/anaplastic medulloblastoma
(Fig. 1). Most medulloblastoma appear sporadically except for a small fraction of patients
that harbor germ-line mutations in tumor suppressor genes, such as those in Gorlin
syndrome (19) and Turcot syndrome (20).

1.3.1. Histopathology
Based on histopathology, medulloblastoma are divided in four SUbtypes: classical
medulloblastoma, desmoplastic/nodular medulloblastoma, medulloblastoma with
extensive nodularity (MBEN) and large/anaplastic medulloblastoma [LAIC, (6, 21)]. Two
tissue patterns are also identified: medulloblastoma with myogenic differentiation
(medullomyoblastoma) and medulloblastoma with melanotic differentiation (melanocytic
medulloblastoma) (6).

Classic medulloblastoma accounts for 65% of cases and is composed of diffused masses
of small, undifferentiated oval or round cells. Desmoplastic medulloblastoma account for
25% of cases and comprise of firm and consistent stroma made-up of recticulin-free
nodule surrounded by proliferative cells. MBEN accounts for 5% of cases and differs
exhibits a markedly expanded lobular architecture and advanced neuronal differentiation.
The LAIC subtype accounts for 5% of cases and are characterized by spherical cells that
have large nuclei, open chromatin and prominent nuclei.
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Fig. 1: Schematic representation of the molecular progression of medulloblastoma
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1.4. MEDULLOBLASTOMA ETIOLOGY
1.4.1. A Change in Normal Development?
It is accepted that there is a link between embryonic development and the biology of

embryonic tumors (22). Many genes that were initially identified as oncogenes and tumor
suppressor genes have been identified as the key regulators of normal developmental
events. This is particularly true in embryonic tumors of the CNS (22). The majority of
these genes regulate the components of Wnt and Shh signaling pathways which activate
c-Myc. It is also clear that many of the pathways required for cerebellum development
are activated in medulloblastoma (16, 17).

1.4.1.1. Wnt Signaling
The Wnt signaling pathway (Fig. 2) is a critical regulator of stem cell (SC) self renewal
and is essential for proper embryonic development. It tightly controls intercellular
communication in mUltiple developmental events and has been implicated in several
diseases, particularly cancer (23,24). The Wnt cascade regulates cell proliferation, cell
fate specifications and cell differentiation through its major effector B-catenin (23). The
stability of B-catenin is regulated by the destruction complex that induces adenomatous
polyposis coli (APC), Axin, glycogen synthase kinase-3B (GSK-3 B) and casein kinase 1a
(CK1a). In the absence of the Wnt ligand, the two scaffolding proteins APC and Axin
bind newly synthesized B-catenin. GSK-3B and CK1a then phosphorylate a set of
conserved Ser and Thr residues on B-catenin. This results in the ubiquitination and
degradation of B-catenin by the proteosome (23,25). Upon activation of the Wnt ligand,
the family of seven transmembrane Frizzle (Fz) receptors is engaged with the low-density
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lipoprotein (LDL) receptor related protein (LRP) complex, Lrp5/6. Binding of Wnt to the
FZ-LRP facilitates reconfiguration of the FZ transmembrane domain. The intracellular
proteins Dishevelled (Dsh) and Axin are recruited to the cell membrane, and
phosphorylation of the cytoplasmic compartment of LRP occurs. In addition, relocation
of Axin to the membrane leads to inhibition of B-catenin phosphorylation and subsequent
inactivation of the destructive complex. This elevates cytoplasmic B-catenin protein
levels, causing B-catenin to enter the cell nucleus, where it interacts with members of the
T cell factor/lymphoid enhancer factor (TcflLef) family of transcription factors. In the
absence of Wnt signaling, TcflLef interacts with Groucho and histone deacetylases such
as Rpd3 to act as repressor of Wnt target genes (26). The binding of B-catenin to TcflLef
relieves the repressive activity of Groucho, and thus activates Tcf target genes such as
cellular myelocytomatosis virus related oncogene (c-Myc) and cyclin D1 [(23,25), Fig.
2]. Activation of Wnt signaling pathway is found in up to 25% of sporadic
medulloblastoma (27). For instance, mutations in components of the Wnt pathway, such
as CTNNBq (encoding B-catenin), APC and Axin, have been demonstrated in
approximately 15% of sporadic medulloblastomas (28-30). Several studies using gene
expression arrays have shown that Wnt signaling is activated in a distinct molecular
subset of medulloblastomas (16, 31, 32).

1.4.1.2. Sonic Hedgehog (Shh) Signaling
Shh signaling is known to regulate growth and patterning during embryonal development.
Recent data suggest that Shh signaling is essential for SC maintenance and regeneration
(33). Germ-line mutations that affect Shh signaling activity are associated with
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developmental disorder, whereas mutations activating the pathway are linked to multiple
forms of cancer including medulloblastoma (34). In the absence of Shh, the 12-span
transmembrane cell surface receptor Patched (Ptch) acts to inhibit the activity of the 7span transmembrane receptor-like protein Smoothened (Smo). Lack of Smo activity
results in phosphorylation of Gli2/Gli3, which is further sequestered in the cytoplasm,
where Gli2/Gli3 forms a complex with Fused and Costal2. Subsequently, Gli3 is
recognized by

~- TrCP

and proteolytic ally processed to generate the truncated repressor

form GliR. This truncated form of Gli3 represses a subset of Shh target genes (33). The
binding of Shh to Patched releases inhibitory activity of Smo, which triggers the activity
of Gli2 (GliA) by inhibiting the major intracellular inhibitor of Gli, Suppressor of fused.
Free GliA can trans locate to the nucleus and activate the expression of target genes such
as MYC, Cyclin D1, Gli-1and Patched [(33), Fig. 2]. Godin syndrome, in which patche
(Ptch) is mutaed, is an autosomal dominant disorder that predisposes individuals to
developmental defects and cancer. About 1-2% of medulloblastoma are attributed to the
syndrome (35). Abnormal Shh signaling activity occurs in approximately 20% of
sporadic medulloblastomas (31, 32).

1.4.1.3. Other Important Signaling Pathways in Medulloblastoma Etiology
c-MET (MET or MNNG HOS) is a proto-oncogene that encodes a protein known as
hepatocyte growth factor receptor [(HGFR) (36)] the only known ligand for the MET
receptor. MET is activated by it ligand HGF eventually leads to phosphorylation and
activation of the p85 regulatory subunit of phosphatidylinositol-3 kinase (PI3K) or
indirectly through the scaffolding protein Gab1(37).
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Aberrantly active MET triggers tumor growth, angiogenesis and metastasis, and this
correlates with poor prognosis in cancer. MET regulates tumor growth, angiogenesis and
metastasis, and this correlates with poor prognosis of cancers. MET is deregulated in
many types of human malignancies, including medulloblastoma. HGF induces tumor cell
proliferation, anchorage-independent growth, and cell cycle progression beyond the G1-S
checkpoint (38). HGF also protects medulloblastoma cells against apoptosis induced by
chemotherapy. This cytoprotective effect was associated with reduction of pro-apoptotic
cleaved poly (ADP-ribose) polymerase and cleaved caspase-3 proteins and required PI3K
activity (39). HGF induces MYC mRNA and c-Myc protein in established and primary
, medulloblastoma cells.

Myc has emerged as an important prognostic indicator and modulator of
medulloblastoma malignancy. It is central to the activity of the Shh, Wnt, c-Met and
insulin growth factor (lGF) pathways which are usually deregulated in medulloblastoma
(31).

1.4.2. Biological and Genetic Marker
The neurotrophin-3 (NT-3) receptor TRKC was the first TRK used as a marker to predict
clinical outcome, and now several TRKs have been correlated with survival in
medulloblastoma patients. NT -3 activates TRKC and regulates proliferation,
differentiation and cell death of the granule cells of the developing cerebellum. High
TRKC mRNA expression is associated with a favorable outcome in medulloblastoma,
with 5yr free survival rate of 89 % vs 46% for low TRKC mRNA expression (40).
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Patients with deregulated Wnt signaling belong to a distinct molecular sub-group of
medulloblastoma (27, 41). Medulloblastoma with Wnt activation are usually associated
with chromosomal loss of 6p (41). Patients with

~-catenin

necleopositivity have a better

overall survival (OS) rate compared to patient without Wnt activation, 92% vs 65% (27,
41). Genetic abnormalities of Shh signaling, as seen in response to mutated Ptchl (the
Shh receptor which acts as a repressor in the absence of the ligand), are responsible for
Godin syndrome, which exhibits high medulloblastoma incidence (42). Mutation of Shh
negative regulators, such as Ptch 1, SuFu and RenlKCTD 11 have all been reported in
sporadic medulloblastoma. Mutations in these upstream regulators have also been shown
to regulates Shh target genes including MYC (17, 43). Genomic amplification of MYC
and the neuroblastoma-derived MYCN is strongly correlated to poor prognosis [5 yr as:
amplified MYC 13% vs not amplified 72% (44,45)]. Low expression of MYC rnRNA
indicates a good prognosis, particularly when found in combination with high TRKC
expression (46).

The most characteristic chromosomal abnormalities in medulloblastoma are 17p deletion
and 17 q gain. Approximately 30% of medulloblastoma patients harbor at least one of
these abnormalities (44). The 5yr as for 17q gain (55%) and isochromosome (35%) are
better predictors of outcome than 17p deletions [78% (44)].

1.5. MYC ONCOGENE
1.5.1. Gene and Protein Product
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The MYC gene was originally identified in avian retroviruses as an oncogene responsible
for inducing myelocytomatosis in birds (47). Its human homologue, c-Myc, was found to
be evolutionarily conserved (48). In mammals, there are four related genes in the family,
c-Myc, N-Myc, L-Myc and S-Myc, with all sharing similar structural framework. c-Myc
is a proto-oncogene and is located on chromosome 8q24.21. The gene product is a
nuclear phosphoprotein with a short half-life of 20-30 mins that is subsequently
ubiquitinated for proteosome degradation (49).

1.5.2. c-Myc as a Transcription Factor
MYC is a basic Helix-Loop-Helix leucine zipper (bHLHZip) protein that heterodimerize

with Max, another bHLHZip protein, with binding ability to consensus 5' -CAC[Cff]
GTG-3'DNA sequences called E-boxes. The basic region promotes sequence-specific
DNA binding; the HLHZip domain confers protein-protein interaction while the Zip
domain functions in maintaining dimerization. It is believed that Myc exerts its main
functions through gene regulation by recruiting transcriptional cofactors involved in
modulation of RNA polymerase II function and chromatin structure, including histone
acetyl transferase (HAT) and transformation/transcription domain-associated protein
(TRRAP) recruitment. These are engaged through interactions with the conserved Mycbox 2 (MB2) in the transactivation domain (TAD) or with the bHLHZip domain (50-52).
While the MB2 domain (spanning residues 128-143) is required for cell transformation
(49,53), the MB1 domain (residues 47-62) is required for c-Myc activity and degradation
(51,54). MB3 plays a role in cellular transformation and MB4 in Myc-induced focus
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formation (55). All four MBs are found in both c-Myc and N-Myc, whereas L-Myc lacks
MB3 (56).

1.5.3. Downstream Effects of c-Myc
MYC protein product is a transcription factor that regulates the expression of -15% of all
genes in the cell. Due to the plethora of target genes c-Myc regulates, it is viewed as a
multifunctional protein with the ability to regulate activities such as cell cycle, growth
and metabolism, differentiation, apoptosis, transformation, genomic instability and
angiogenesis (50, 51).

1.5.3.1. Cell Cycle and Differentiation
As Myc is essential for GO/G 1 to S-phase cell cycle progression, cells with activated Myc
have a shortened Gl phase (57, 58). Myc abrogates the transcription of cell cycle
checkpoint genes (for example, Gadd45a and Gadd153) and inhibits the function of
cyclin-dependent kinase (CDK) inhibitors, either through directly repressing gene
transcription or indirectly through degradation or sequestration. Myc also promotes cell
cycle progression by activation of cyclin Dl, cyclin D2, and cyclin A, as well as Cdk4,
cell division cycle 25A (CDC25A), and E2 promoter binding factor (E2F) 112 (59,60).
Some examples of c-Myc target genes are ornithine decarboxylase (ODC), and Cyclin E
(50,61). Ornithine decarboxylase (ODC) controls polyamine biosynthesis which is
essential as s modifier of ion transport channels, regulate protein translation, Okazaki
fragment joining during DNA replication and progression through S phase of cell cyclin
(62). Cyclin E, with its partner kinase Cdk2, regulates the G 1 to S-phase transition and
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promotes DNA replication (63). c-Myc mediated ODC and Cyclin E up-regulation may
contribute to an oncogenic phenotype as ODC over-expression in mouse fibroblasts
results in transformation (64).

MYC has also been found to be important during cellular differentiation. Downregulation of Myc is required for cells to exit the cell cycle and undergo differentiation.
This important point of regulation is further enforced by the induction and function of the
Mxd family members in response to differentiation cues (57, 65).

1.5.3.2. Cell Growth/Proliferation
The ability of Myc to promote cell growth has been demonstrated in vitro and in vivo.
Myc enables cell growth by providing the cell with an abundant supply of several classes
of basic building blocks as well as increasing cell metabolism and protein synthesis (66).
Myc-induced cell proliferation is potentiated by several Myc target genes, including those
associated with cellular metabolism, ribosomal and mitochondrial biogenesis, and protein
and nucleic acid synthesis (67, 68). Gadd45a and ODC are specific c-Myc targets that
have been implicated in c-Myc-mediated cell growth and proliferation. Equally, c-Myc
has been shown to down-regulate both basal and stress-induced Gadd45 expression (69).
Gadd45a has been shown to function in growth arrest and in apoptosis following
genotoxic stress (70).

1.5.3.3. Genomic Instability
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S. Mai and colleagues showed that specific gene amplification occurs at a high frequency
in cells with deregulated Myc (71). Additional research shows that Myc can promote
chromosomal instability (72, 73). However, the role of Myc in genomic instability has
been a subject of debate and controversy (74). Several mechanisms have been proposed,
including increased levels of reactive oxygen species, alterations in chromosome
structure (75), overcoming the p53 checkpoint (75), and induction of a DNA damage
response and/or replication (76). Losing the high-fidelity organization of the genome is a
hallmark of tumorigenesis that can clearly be associated with Myc deregulation.

1.5.3.4. Metastasis and Angiogenesis
Down-regulation of thrombospondin is vital to angiogenesis and is potentially achieved
through Myc induction of the miR-17 -92 cluster (77). The role of Myc expression during
normal development is associated with proliferative expansion and cellular migration.
Recent reports have demonstrated that c-Myc expression is required for the activation and
expression of miR-9 (78-80). miR-9 negatively regulates E-cadherin, which results in
activation of ~-catenin and in tum contributes to cell metastasis and angiogenesis (80).
The relevance to tumorigenesis is intuitive, with deregulated MYC preventing
differentiation and promoting migration, leading to the features of aggressive, less
differentiated, metastatic cancers.

1.5.3.5. Induction of Apoptosis
One of the functions of Myc is induction of apoptosis in response to cellular stress.
Cyclin A and ODC are central to c-Myc-mediated apoptosis. Inhibition of ODC blocks
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inhibits apoptosis in c-Myc-over expressing cells, and forced expression of Cyclin A is
sufficient to induce apoptosis under low serum conditions (81). c-Myc-mediated
apoptosis correlates with regulation of the Fas receptor and its ligand as well as
proapoptotic Bax (82). Despite modest change in Bax levels upon c-Myc overexpression (83), Bax appears to be essential for c-Myc-mediated apoptosis by indirect upregulation of upstream molecules like Caspase 8 (84). Furthermore, in response to c-Myc
activation and MYClRas-induced transformation, p53 can be up-regulated and stabilized
to induce cell cycle arrest or apoptosis (85). Furthermore, c-Myc-mediated apoptosis
might be due to accumulation of reactive oxygen species (ROS) as a consequence of NFKB inhibition (86).

1.5.3.6. Regulation of 'Sternness'
Experiments in transgenic mice have revealed that expression of c-Myc is essential for
normal developmental control of haematopoietic stem cells (HSC) and neural stem cells
(87, 88). Knockout of MYC in immature HSCs results in pancytopenia and rapid lethality
(89). Likewise, c-Myc is crucial for self-renewal and maintenance of pluripotency in
murine ES cells (90). More evidence demonstrating the importance of c-Myc in
'sternness' comes from experiments where murine and human somatic cells were
reprogrammed to pluripotency through the generation of induced pluripotent stem cells
(iPS) by retrovirus-mediated introduction of Oct3/4, Sox2, Klf4 and c-Myc (91).
Although a recent report shows that c-Myc may be redundant in the conversion of
somatic cells to iPS cells (92), there is still an implication for a novel 'sternness' function
of c-Myc that may be important for controlling tumor-initiating cells. The pluripotent
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ability of c-Myc has been connected to its ability to positively regulate the cell cycle
machinery (93). Consistently, down-regulation of c-Myc correlated with the
differentiation of pluripotent cells (90).

1.5.4. MYC in Medulloblastoma
Over-expression of c-Myc in medulloblastoma has been associated with poor prognosis
and the prognostically dismal large cell/anaplastic medulloblastoma subtype (94-96). Shh
signaling corporate with c-Myc to enhance tumorigenicity of Nestin-expressing neural
progenitors that are present in the cerebellum at birth. The Nestin-expressing neural
progenitor cells can act as the cells-of-origin for medulloblastoma (97). c-Met induces cMyc, which mediates medulloblastoma cell proliferation, cell cycle progression,
apoptosis and increased cell size (39). In cultured granule neuron precursor (GNP) cells,
insulin growth factor (IGF) signaling stabilizes Myc by inhibiting GSK3p-dependent
phosphorylation, thus preventing degradation of Myc. Similarly, Myc can substitute for
IGF signaling in a mouse model of Shh-induced medulloblastoma (98). Therefore, Myc
appears to playa central role in mediating the effects of the signaling pathways in
medulloblastoma including Shh, Wnt, c-Met, and IGFR. Therefore, it represents an
attractive target for the therapy of this neoplasm, especially the very aggressive large
cell/anaplastic subtype. Unfortunately, clinically useful inhibitors of Myc are not
available to date.

Over-expression of c-Myc is found in -31-64% of medulloblastoma patients (96), but
only 5-15% of them have MYC gene amplification (94, 99, 100). Various means of
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amplification-independent c-Myc activation have been identified in other human cancers:
chromosomal translocations in Burkitt's lymphoma constitutively activate mRNA
expression (101); c-Myc expression in multiple myeloma are increased 20-fold by a
mutation in the 5' untranslated internal ribosome entry segment (102); mutations at the
Myc intron factor binding site in mucosa-associated lymphoid tissue lymphomas removes
a negative regulatory sequence (103); and APC or

~-catenin

mutations in colon cancer

activate the c-Myc promoter at a ~-cateninITcf-4 transcription factor binding site (104).
APC and

~-catenin

mutations have also been found in a small fraction of

medulloblastoma (30), and nuclear

~-catenin

staining was reported in 18% of

medulloblastoma studied (29). Therefore, genomic amplification-independent activation
of c-Myc is a likely mechanism for tumor progression of medulloblastoma.

1.5.5. Regulation of MYC
In normal cells Myc expression and activity is regulated at multiple levels. At the
transcriptional level, Myc is regulated by signal transduction pathways that are activated
both during normal development and in cancer. The most important include Shh, Wnt,
Notch, RTK signaling and transforming growth factor

(TGF)-~.

Posttranslationally, c-

Myc is regulated through sequential and reversible phosphorylation at two conserved
sites, threonine 58 (T58) and serine 62 (S62), located on the amino-terminal TAD of the
protein (54). T58 phosphorylation stimulates ubiquitination and proteasomal degradation
by SCFFBW7 (105), while S62 phosphorylation stabilizes c-Myc. It has been hypothesized
that GSK-3~-mediated phosphorylation of c-Myc at T58 and dephosphorylation at S62
allows for binding of ubiquitin ligase FBW7 and recruitment of SCF FBW7 complex to
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direct c-Myc degradation. Coupled to FBW, F-box protein Skp2 and Hect H9 are two
other ligases involved in c-Myc turnover (106). Skp2 effects transcriptional activation
and degradation (107) while Hect H9 promotes transcriptional activity only (106).
Proteins such as Ras, frequently altered in human cancers, can lead to inhibition of GSK3~

activity and subsequent stabilization of c-Myc protein through loss of T58

phosphorylation (108).

GSK-3~

acts as a key protein in the canonical Wntl~-catenin

signaling pathway by regulating the activity and nuclear transportation of ~-catenin,
which subsequently leads to transactivation of MYC (104).

1.6. MicroRNA (miRNA)
MiRNAs are small non-coding RNAs (18-25 nuc1eotides), involved in repression of gene
expression by binding to the mRNA 3 'untranslated region (3' UTR), and effecting either
translational repression, or mRNA degradation in animals, plants and protozoa. In
mammals miRNAs are predicted to control the expression of more than 60% of all
protein-coding genes (109), and are thereby involved in nearly all cellular processes.

1.6.1. miRNA Biogenesis
Individual miRNAs can be transcribed separately from a single transcriptional unit,
which can encode a single miRNA or a cluster of distinct miRNAs; or they can be
processed directly from other RNA species, such as introns (Fig. 3). Transcription of
miRNAs by RNA polymerase II results in primary miRNA transcripts (pri-miRNAs),
which are 5' capped and polyadenylated at the 3' end. The pri-miRNAs transcript is then
cleaved in the nucleus by Drosha, an RNase III endonuclease, in association with
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DGCR8IPasha, the double-stranded RNA-binding domain protein, in a complex known
as the microprocessor complex (110). Drosha cleaves both strands of the stem at sites
near the base of the primary stem-loop to generate an intermediate called precursor
miRNA (pre-miRNA). The pre-miRNA is exported out of the nucleus with the aid of the
nuclear membrane bound export in 5. In the cytosol the RNase III domain-containing
nuclease, Dicer, cleaves the terminal loop to generate the -22 nucleotide mature miRNA.
Dicer functions in combination with the double-stranded RNA-binding domain protein
TRBP and PACT (111). The mature double-stranded RNA duplex that results from Dicer
cleavage is unwound and then loaded into the RNA-induced silencing complex (RISC).
RISC is a complex composed of Dicer, TRBP and a protein of the argonaute superfamily
(112). The complex identifies target mRNA based on sequence complementarity between
the miRNA and the associated single-stranded mRNA's 3'UTR, resulting in either
mRNA cleavage or translational repression (113). Two basic mechanism have been
proposed for miRNA gene silencing: initiation block, where the miRISC inhibits
translation initiation by interfering with the eIF4F-cap recognition and 40S small
ribosomal subunit recruitment or by antagonizing 60S subunit joining and preventing 80S
ribosomal complex formation (114); and post-initiation block, where the miRISC inhibit
translation by inhibiting ribosome elongation, inducing ribosome drop-off, or facilitating
proteolysis of nascent polypeptide (115).

1.6.2. miRNAs and Cancer
About 50% of annotated human miRNAs are mapped in fragile regions of chromosomes,
which are areas of the genome prone to 'genomic earthquakes, that can trigger
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chromosome rearrangement, disrupt genes and alter gene regulation. These genomic
regions are associated with various human cancers (116-118). The relevance of miRNAs
to cancer is highlighted by their differential expression patterns in cancerous cells
compared to normal cells. Several miRNAs have emerged as candidate components of
oncogene and tumor-suppressor networks. The miR-17-92 cluster (119, 120), and miR155IBIC (121) have been implicated as proto-oncogenes in B-celllymphomas. On the
other hand, let-7 tumor suppressive function has been validated in various cancers (122,
123). Many of the oncogenic or tumor-suppressor miRNAs target cell cycle regulators,
and this interaction may at least partially explain the oncogenic function of the miRNA
alteration in cancer cells. miRNAs act as oncogenes and tumor suppressor genes and
induce all of the six hallmarks of malignant cells.

1.6.2.1. Self-sufficiency in Growth Signals
To become independent from external growth factor signals and evade tissue
homeostasis, tumor cells activate different pathways to sustain cell proliferation and
survival such as the RAS proteins, H-RAS, K-RAS, and N-RAS. RAS oncogenic
signaling is activated in response to decreased levels of let-7, a well-documented posttranscriptional RAS regulator that is inversely correlated with RAS expression in solid
and hematologic malignancies (122). Let-7 down-regulation is associated with poor
prognosis in lung cancer patients (124) and head and neck squamous cell carcinoma
patients (125). Let-7 acts as a tumor suppressor by targeting oncogenes such as RAS and
HMGA2 and is down-regulated in many solid cancers (126).
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Reduced Let-7expression result in up-regulation of the high-mobility group AT -hook 2
(HMGA2), which helps tumor cells grow in an anchorage-independent manner and not
undergo apoptosis after they lose contact with the basal membrane. The clinical relevance
oflet-Ts anti-proliferative effects was recently demonstrated by let-7-induced tumor
regression in in vivo murine lung cancer models (124). Also, miR-21, one of the most
frequently up-regulated miRNAs in solid tumors, also participates in RAS oncogenic
signaling. API that acts downstream of RAS transcriptionally induce miR-21 which
exerts its oncogenic effect by keeping phosphatase and tens in homolog (Pten) and
PDCD4 in check (127). PDCD4, in turn negatively controls API, thus API-induced miR21 represents a positive feedback loop that sustains API activity in response to RAS
(127). miR-21 overexpression enhances tumorigenesis, and genetic deletion of this
oncogenic miRNA partially protects against tumor formation in transgenic mice (128,
129).

1.6.2.2. Insensitivity to Anti-Growth Signals
The retinoblastoma (RB) pathway is one of the major cell cycle regulatory routes that is
altered in almost all human cancer cells (130). RB is a transcriptional repressor that
inhibits members the E2F family, resulting in proliferative arrest and inhibition of the
expression of genes required for cell cycle progression such as MYC. The RB pathway is
defective in a wide range of human tumors, resulting in deregulated and hyperactive E2F
in transformed cells and uncontrolled cell proliferation (131). E2F transcription factor
activities are controlled at the post-transcriptional level by a series of miRNAs including
miR-17-5p, miR-20a, miR-106b, and miR-92 (119,132,133). Furthermore, E2F-
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activating transcription factors have been shown to regulate the expression of miRNAs
(132, 133). Unbound E2F increases miR-17-92 and miR-106b-25 expression which in
turn keeps E2F levels in check through miR-17-5p and miR-20a (119), thereby
participating in the delicate equilibrium between cell proliferation and apoptosis. Upregulated miRNAs from these clusters target apoptotic and growth inhibitory proteins
such as BIM and p21 (132). Under physiologic conditions, the miR-17-92 cluster limits
MYC activation by dampening the E2F positive feedback loop. In tumors with MYC
activation, the miR-17-92 cluster protects cells from Myc-induced apoptotic E2F
response, leading to uncontrolled cellular proliferation. Also, miR-106b-25 family
members are found to be induced in gastric cancer (132) and negatively regulate
excessively high E2F1 expression levels that cause tumor cell apoptosis. miRNAs also
play roles in activating cell cycle progression by targeting cell cycle checkpoint proteins.
The miR -15a-16-1 cluster induces cell cycle arrest at G 1 phase by targeting critical cell
cycle regulators such as CDK1, CDK2 and CDK6 as well as cyclins (D1, D3 and El)
(134, 135). In fact, these major cell cycle kinase complexes are regulated by several other
miRNAs. CDK4 or CDK6 mRNAs are targeted by miR-24, miR-34a, miR-124, miR125b, miR-129, miR-137, miR-195, miR-449 and let-7 family members (136, 137). As
expected, most of these miRNAs display anti-proliferative properties, function as tumor
suppressors and are inactivated in cancer by different mechanisms (138). Finally, some
cell cycle inhibitors of the INK4 or Cip/Kip families are also tightly regulated by
miRNAs. p16 INK4a , a CDK4/6 specific inhibitor, is controlled by miR-24 and miR-31
(139). Both miRNAs are involved in the regulation of cell proliferation and progress
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through the cell cycle at least in part by regulating the levels of the p16 INK4a CDK
inhibitor.

1.6.2.3. Apoptosis
Apoptosis is a physiologic self-destruction mechanism that leads to the removal of
unwanted cells. P53 is the most widely studied transcription factor; it controls the
expression of several genes to promote tumor suppression. p53 responds to diverse
cellular stresses and regulates target genes involved in DNA integrity, cell cycle arrest at
the G 1/S checkpoint, and apoptosis. It is the most commonly mutated gene in human
cancer. miRNAs such as miR-34, miR-192/215, miR-107, and miR-145 are known
transcriptional targets of p53 (140). The cancer-associated genomic region 1p36, which is
lost or rearranged in many tumor types, including those from neural, epithelial, and
hematopoietic tissues, contains the candidate tumor suppressor miR-34a. The miR-34
family is composed of three evolutionarily conserved members: miR-34a, miR-34b, and
miR-34c. miR-34a functions as a potent suppressor of cell proliferation by modulating
E2F signals (141) and induces p53 in a cell-type specific manner to activate apoptosis.
Other major pro-apoptotic miRNAs with reduced expression in tumors include the miR15a/16-1 cluster, which represses anti-apoptotic Bcl2 protein and activates the intrinsic
apoptotic program APAF-1-caspase-9-poly (ADP-ribose) polymerase (142). miR-15a and
miR-16-1 are clustered on human chromosome 13q14, which is frequently lost or downregulated in B-cell chronic leukemia and several solid tumor types (142).

1.6.2.4. Limitless Replicative Potential
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Cellular senescence is a physiologic withdrawal from the cell cycle in response to a
multitude of different stress stimuli, including oncogene activation, and telomere
deregulation (143). It is executed by two important cell cycle inhibitors, p21 and p16
(144) which are activated upon cellular stress. Also, various stresses can induce
senescence, but p53 and RB have been identified as critical pathways common to the
initiation, execution, and maintenance of senescence-associated growth arrest. P53activated miRNAs such as miR-34 are also important in senescence by modulating the
E2F signaling pathway (145, 146). Furthermore, 15 miRNAs have been found to be
down-regulated in senescent cells and breast cancers harboring wild-type p53, which
demonstrated that these miRNAs are repressed by p53 in an E2F1-mediated manner
(147). Recently, the protein subunit TERT of telomerase was found to be a direct target
of regulation by miRNAs such as miR-138, miR-143, and miR-146a (148, 149).

1.6.2.5. Angiogenesis
Tumor cells tum on an "angiogenic switch" to produce large amounts of pro-angiogenic
factors and promote vascularization. Hypoxia adaptation is an essential cellular response
that is controlled by vascular endothelial growth factor (VEGF), which is also regulated
by the oxygen-sensitive master transcription factor hypoxia-inducible factor 1 (HIF-1).
HIF-1 expression is controlled by specific miRNAs such as the p53-induced miR-107 and
miR-92 that target the Von Hippel-Lindau gene whose product is responsible for HIF-1
degradtation (150, 151); it, in tum, controls the expression of other miRNAs (152-154)
that fine-tune adaptation to low oxygen tension. In tumor progression, hypoxia has been
found to contribute to the modulation of miRNA expression, partly by direct HIF-1
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transcriptional activation of specific miRNAs such as miR-424 and miR-210 (152-154).
These miRNAs have dual functions: they participate in the angiogenic process while
helping the cell engage anti-apoptotic programs that sustain survival. miR-126 expression
was found to be enriched in endothelial cells during angiogenesis and to repress negative
regulators of the VEGF pathway (SPRED1 and PIK3R2) (155). miRNAs that are downregulated in hypoxic conditions, such as miR-16, miR-15b, miR-20a, and miR-20b,
directly modulate VEGF expression levels. This creates a positive feed-forward loop in
which hypoxia-repressed miRNAs reinforce the expression levels of a potent proangiogenic hypoxia-induced growth factor, such as VEGF (156). Lastly, individual
miRNAs in the miR-17-92 cluster have effects on angiogenesis with miR-17-5p, miR19a and miR-18a contributing directly to angiogenesis (157).

1.6.2.6. Invasion and Metastasis
The metastatic process involves multiple steps which culminate in tumor cells spreading
to distant organs. The deregulation of epithelial-to-mesenchymal transition gives cells
migratory and invasive properties that promote the dissemination of tumor cells and
metastasis. Recent studies have shown that members of the miR-200 family (miR-141,
miR-429, miR-200a, miR-200b, and miR-200c) are essential regulators of differentiation
and epithelial cell character through the targeting of the zinc finger E-box-binding
homeobox (Zeb) family of transcription factors (158, 159). Zeb1 and Zeb2 are master
regulators of the mesenchymal phenotype and repress the transcription of genes
containing E-box elements in their promoters, including E-cadherin. Twist, a metastasispromoting transcription factor, was found to induce miR-lOb expression, whereas
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HOXDlO, a homeobox transcription factor that promotes or maintains a differentiated
phenotype in epithelial cells, is found to be a miR-lOb target that is expressed at low
levels in metastatic tumors (160). miR-21 does not only control cell survival and
proliferation; it is also a master regulator of the metastatic process by directly modeling
the cell cytoskeleton via TPM1 suppression (161, 162) and by indirectly regulating the
expression of the pro-metastatic uPAR (via Maspin and PDCD4 direct suppression)
(161), matrix metalloproteinases (via RECK and TIMP3) (163), and Pten direct
suppression (164).

1.6.3. Chemotherapeutic Importance of miRNAs
RNA-based gene therapy can be used to treat cancer in two ways: by using RNA
molecules against the mRNA of genes involved in cancer pathogenesis; or by directly
targeting the miRNAs that participate in pathogenesis. It is recently reported that
therapeutic miRNA delivery suppresses tumorigenesis in a murine liver cancer model:
hepatocellular carcinoma cells exhibit reduced expression of miR-26a and systemic
administration of miR-26a in a mouse model of hepatocellular carcinoma using adenoassociated virus results in inhibition of cancer cell proliferation, induction of tumorspecific apoptosis, and dramatic protection from disease progression without toxicity
(165). Antagomirs are therapeutic RNA molecules that were originally designed to inhibit
miRNAs (166, 167). Antagomirs' anti-cancer activity was demonstrated in a
neuroblastoma model in which cholesterol conjugated antagomir-17 -5p delivery resulting
in regression of neuroblastoma in 30% of cases (168). Another method of targeting
miRNAs is through locked nucleic acid (LNA)-mediated miRNA silencing. Efficient
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miR-122 silencing was achieved with three doses of 10 mg/kg LNA-anti-miRNA. MiR122 is an abundant liver specific miRNA, implicated in fatty acid and cholesterol
metabolism and hepatitis C replication leading. The LNA-miR-122 be exhibited a longlasting and reversible decrease in total plasma cholesterol and no evidence of associated
toxicities or histopathologic changes in the liver (169). Despite the promising result, the
use of miRNA therapy has not been successful in humans due to constrains such the large
size of miRNAs or anti-miRNA thereby failing one of the Lipinski rule of five for druglikeliness. In addition the molecules are likely recognized as foreign and elicit immune
responses. Furthermore, miRNAs are expected to have low stability in vivo since they can
be degraded by endogenous RNases.

1.6.4. miRNAs and Medulloblastoma
Peirson and associates were the first to demonstrate that miRNA could regulate
medulloblastoma development. They showed that miR-124, a brain enriched miRNA,
was significantly down-regulated in medulloblastoma and augmentation of miR-124
reduced medulloblastoma cell growth by targeting CDK6 (136). Since then, roles have
been attributed to miRNAs in modulation of the Shh signaling and Notch (170). For
example, RES1, the principal Notch-responsive gene, has been shown to be negatively
regulated by miR-199b-5p, resulting in reduce cell proliferation and migration of
medulloblastoma cells (171). Moreover, other investigators have focused on miRNA
profiling of medulloblastoma cell lines in various cellular states and have identified
important miRNA signature patterns in medulloblastoma development (172, 173). These
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experiments have all highlighted the importance of miRNA in medulloblastoma
development and their therapeutic potential.

1.6.5. Myc-miRNA Regulatory Network
The transcription factor, c-Myc, also controls the production of many non-coding RNAs,
including tRNA, rRNA and miRNAs. These RNAs are likely to contribute to the
complex biology and pathology that is associated with changes in c-Myc expression
(174). MYC and miRNAs form complex network, with a number of miRNAs reported to
target MYC and c-Myc regulating the expression some miRNAs. J.T. Mendell and
coworkers reported the direct induction of the miR-17-92 cluster by c-Myc (119). This
cluster of six miRNAs is an oncogene and cooperates with c-Myc to accelerate tumor
development in a mouse model of B-celllymphoma (120). This cluster, as well as the
paralogous cluster miR-106a-92 induced by N-Myc, promotes cell cycle progression in
neuroblastoma cells (175). Both c-Myc and MYCN also induce miR-9, a miRNA that
targets CDH1, encoding E-cadherin, leading to increased cell motility and invasiveness,
as well as increased tumor angiogenesis (80). c-Myc participates in the tumor-associated
repression of miRNAs by directly repressing several miRNA clusters such as miR-15a16-1, miR-22, miR-23a/b, miR-26, miR-29 and severallet-7 clusters (176). Many of
these miRNAs down-regulated by c-Myc are known tumor suppressors and target critical
cell cycle regulators (177, 178). Although most of these miRNAs are down-regulated
through the transcriptional repressor activity of c-Myc, c-Myc may also lead to miRNA
down-regulation by alternative mechanisms. For example, c-Myc is able to block the
maturation of specific miRNAs by inducing the RNA binding proteins Lin28 and Lin28b
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(176, 179), which are known to act as negative regulators of let-7 maturation at multiple
levels including Drosha and Dicer processing (180). Repression of multiple miRNAs by
c-Myc is likely to be an important mechanism contributing to the reduced function of
miRNAs in cancer cells (180).

1.7. RESEARCH THEME
Given the convergence of miRNAs and c-Myc, my dissertation studies focus on: (i)
whether and which miRNAs target c-Myc; (ii) whether the repression of MYC by miR33b is sufficient to reduce medulloblastoma tumor growth; (iii) whether we can identify
the US Food and Drug Administration (FDA)-approved drugs that induce miR-33b
expression to inhibit c-Myc expression and function in medulloblastoma; and, (iv)
whether epigenetic silencing of miR-33b gene is responsible for the reduced sensitivity to
lovastatin in HeLa cells.

First, I identified that miR-33b is a primate-specific negative regulator of c-Myc. The
human miR-33b gene is located at 17pl1.2, a genomic locus frequently lost in
medulloblastomas. Through a small-scale screening with drugs approved by the FDA, I
found that lovastatin upregulated miR-33b expression, reduced cell proliferation, and
impaired c-Myc expression and function in miR-33b-positive medulloblastoma cells. In
addition, a low dose of lovastatin treatment at a level comparable to approved human oral
use reduced tumor growth in mice orthotopically xenografted with cells carrying miR33b, but not with cells lacking miR-33b. This work presents a highly promising
therapeutic option, using drug repurposing and a miRNA as a biomarker, against cancers
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that over-express c-Myc. I also revealed that the promoter of the miR-33b gene is
methylated in HeLa cells but not in medulloblastoma cells, which may contribute to the
lower sensitivity to lovastatin of HeLa cells. This information is critical to future drug
development against cancers other than medulloblastoma using miR-33b and c-Myc.
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CHAPTER 2
MICRORNA-33B (MIR-33B) TARGETS MYCAND NEGATIVELY AFFECTS
MEDULLOBLASTOMA GROWTH.
2.1. INTRODUCTION
The MYC gene codes for the c-Myc onco-protein and is over-expressed in the majority of
human cancers. It is now well established that the deregulated expression of c-Myc plays
a significant role in human cancer development (181-183). The importance of c-Myc in
carcinogenesis is supported in animal models; over-expression of Myc in mouse liver
induces hepato-cellular carcinoma, which regresses if Myc expression is inactivated
(184). c-Myc is a transcription factor that exert its biological functions through activating
and repressing target genes (185, 186). Its expression is tightly control and activated
mitogenic cues resulting in cell proliferation (183).

Treatment of medulloblastoma remains problematic due to high doses of radiotherapy
and chemotherapeutics that lead long-term toxicity. A major focus is the development of
innovative approaches such as targeted therapies to reduce long-term toxicity. c-Myc is
over-expressed in up to -31-64% of medulloblastoma (187) and has been associated with
the large-cell/anaplastic subtype and poor survival (187). However, only -5-15% of
medulloblastoma show an amplification of the MYC gene (188) suggesting that other
mechanisms account for the increased c-Myc expression. Understanding how MYC is
regulated in medulloblastoma is critical to develop targeted therapies.
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Gene profiling and murine models have revealed that many of the pathways (Wnt, Shh,
Myc and Notch) required in neural stem cells (NSC), multipotent cerebellar SCs and
lineage-restricted progenitors of the EGL are also aberrantly activated in
medulloblastoma (17, 189). Inactivation of Ptch in lineage-restricted granule cell
progenitors and NSC has been shown to form medulloblastoma tumors (190, 191).
Experiments in transgenic mice have revealed that expression of c-Myc is essential for
normal developmental control of hematopoietic stem cells (HSC) and NSCs (87, 88).
Likewise, c-Myc is crucial for self-renewal and maintenance of pluripotency in murine
ES cells (90). Therefore, c-Myc is an attractive therapeutic target to inhibit
medulloblastoma cell growth. miRNAs are negative regulators of gene expression and
have been implicated in regulation of cellular processes. Myc regulates miRNA
expression and is also regulated by miRNAs (176, 192, 193). We intend to identify
miRNAs that target MYC as a first step toward the development of potent c-Myc
inhibitors.

We used a screening method, which employs a two-tiered assay to enable us to identify
miRNAs that target MYC directly. Tier 1 is designed to identify miRNAs that function in
a particular pathway and tier 2 is designed to determine which miRNAs targets a specific
3'UTR. We found that miR-33b adversely regulates c-Myc through direct binding to the
3' UTR of the MYC gene. Real-Time PCR data suggests that over-expression of miR-33b

results in decreased levels of MYC mRNA. Also, miR-33b over-expression leads to
down-regulation of c-Myc protein expression, and reduces c-Myc-mediated cellular
proliferation, cell cycle progression, colony formation and cell migration. Furthermore,
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miR-33b expression in D283-Med (D283) cells reduces neurosphere formation.
Orthotopic injection of mice with miR-33b-expressing D283 resulted in decreased in vivo
tumorigenesis. These results demonstrate that miR-33b is able to inhibit cell proliferation,
cell cycle progression and suppress medulloblastoma tumor growth.

2.2. MATERIALS AND METHODS
2.2.1. Cell culture
HEK293T cells were purchased from ATCC and cultured in Dulbecco's modified
eagle's medium (DMEM) (Gibco, Carlsbad, CA) supplemented with 10% heat
inactivated fetal bovine serum (FBS) and 0.1 % (v/v) Antibiotic-Antimycotic (Cellgro,
Manassas, VA). Rat fibroblasts Ratlc-Myc-I- (clone HOI5.19), (from Dr. Claycomb's
Lab, Brown University) were maintained in DMEM (Gibco, Carlsbad, CA) supplemented
with 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA) and 0.1 % (v/v) AntibioticAntimycotic (Cellgro, Manassas, VA). Medulloblastoma cell lines, D283 and DAOY,
were purchased from ATCC and cultured in EMEM (Gibco, Carlsbad, CA) supplemented
with 10% FBS and 0.1 % (v/v) Antibiotic-Antimycotic (Cellgro, Manassas, VA). For
neurosphere formation, D283 cells were cultured in neurobasal media supplemented with
10% FBS (Gibco, Carlsbad, CA), 0.1 % (v/v) antibiotic-Antimycotic (Cellgro Manassas,
VA), 2 mM L-glutamine, N2 supplement, B27 supplement, 20 ng/ml hrEGF, 20 ng/ml
hrbFGF and 50 J.lg/ml BSA (Invitrogen, Carlsbad, CA). All cell lines were cultured at
37°C in an atmosphere containing 5% CO2 •
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Transient transfection was performed using Lipofectamine LTX (Invitrogen, Carlsbad,
CA). Transient transfection efficiency for 293T cells was >90% as judged by a control
vector, pSIF, expressing green fluorescent protein (GFP). Efficiency for other cells lines
was determined based on the expression of GFP from the parental pSIF vector and was
recorded to be between 60-90%. For miRNAs, we used the parental vector pSIF as a
vector control. For inhibitor of miR-33b, we used Anti-miRTM miRNA inhibitor (Ambion
Inc, Austin, TX), which is chemically modified, single stranded antisense RNA to
miRNA designed to specifically bind and inhibit the endogenous miR33b molecules. The
negative control (Ambion, Inc., Austin, TX) used for the inhibitor is a random-sequence
RNA molecule that has been extensively tested in many human cell lines and tissues and
validated to not produce any identifiable effect on known miRNA function.

Stable transfection was performed using viruses generated in 293T cells. For lentivirus
production, 293T cells was transiently co-transfected, 24hrs post plating in 6-well plates,
with 2f.1g of pSIF vector, or miRNA, 1.4f.1g of pVGV-S and 0.7f.1g of pFIV-34N packing
and expression vectors respectively using Lipofectamine LTX. For retrovirus production,
293T cells in 6-well plates were transfected with 2f.1g pCL-Eco and the vector of interest
(pMX-EGFP as control and pMX-gene X for experiments). The lentivirus-containing or
retrovirus containing media was collected after 48 hrs. The viral media was supplemented
with polybrene (final concentration 5-8f.1g/ml), a polycation that neutralizes charge
interaction to increase binding of the virus capsid to the cellular membrane, and used to
infect desired cells. The media was changed after 12-24 hrs to minimize the toxic effect
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of polybrene on cell viability. The efficiency of stable transfection was determined based
on expression of GFP or RFP by fluorescent microscopy.

2.2.2. Cloning
MYC 3'UTR primers were designed using the Vector NTI software: forward primer 5'ATTCTAGAGGAAAAGTAAGGAAAACGATTCCT-3' and reverse primer 5'TAGCGGCCGCGGCTCAATGATATATTTG-3'. The MYC 3' UTR primers were
modified at both ends to carry Notl and XbaI sites. The primer set was used to amplify
the 3 'UTR of MYC by PCR in a mixture of 0.5
buffer H, 2.5

~l

~l

of 100~M of each primer, 25

ofTaq polymerase (Promega, Madison, WI), 0.5

~l

~l

of 2x

of lOmM dNTPs

(Promega, Madison, WI) and 100 nM of A459 genomic DNA template. The amplified
3'UTR (467bp) was purified from a 1% agarose gel using Ultrafree-DA columns
(Millipore Inc., Billerica, MA) and cloned into pGEM-T vector (Promega, Madison, WI).
The resultant pGEM-T -MYC 3' UTR WT was digested with NotIlXbaI (New England
BioLabs, Ipswich, MA) and cloned into the Notl and Xbal site of pRL-TK vector.

The following primer set: reverse 5' GGC AGT TTA AGC CAT GGC TAA 3'; forward
primer 5' -ATTCTAGAGGAAAAGTAAGGAAAACGATTCCT -3'; mutant primer
5'GGCAGTTTAAGCCATGGCTAA3'; was used to clone the full mutantMYC 3'UTR,
mutated at the miR-33 'seed' binding site, into the XbalINotl sites of pRL-Tk vector in 2
PCR runs. In the first PCR the WT forward primer and the mutant primer were used to
amplify an approximately 150bp product. The first PCR product was used as a forward
primer for the second PCR, with the WT reverse primer to amplify the full length mutant
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MYC 3' UTR. The product was purified using the Ultrafree-DA column (Millipore Inc.,
Billerica, MA) and cloned into pGEM-T vector (Promega, Madison, WI). This resultant
pGEM-T-MYC 3'UTR mutant was cut with Notl and XbaI and cloned into the
NotllXbaI site of pRL-TK vector. Likewise, the following primer set: reverse 5' GGC
AGT TTA AGC CAT GGC TAA 3'; forward primer 5'ATTCTAGAGGAAAAGTAAGGAAAACGATTCCT-3'; mutant forward primer 5'
GTACCTAAGCGGCTAGGTACTA 3' was used to clone mutantMYC 3'UTR mutated
at the miR-369-5p 'seed' binding site into the XbalINotl site of pRL-TK.

The oligonucleotides listed in Table 1 were used to clone the miR-33b mutant construct.
The oligonucleotides were phosphorylated in a mixture containing 5 J11 of lOJ1M of each
oligonucleotide (except for 1 and 9), IX of T4 polynucleotide kinase (PNK) buffer,O.5J11
of T4 PNK (New England BioLabs, Ipswich, MA), and of IJ1M ATP at 3TC for
30minutes. PNK was inactivated by incubating at 65°C for 5 minutes. The
oligonucleotide was then annealed by heating at 90°C for 5 mins and eventual cooling to
room temperature. The annealed product was adenylated by incubating with dATP at
72°C for 30mins. The resultant pGEM-T-miR-33b mutant construct, as well as pSIF
vector, were digested with MfeI and BamHI and the desired bands, 150bp and 7kb
respectively, purified with the Ultrafree-DA column (Millipore Inc., Billerica, MA). The
mutant miR-33b insert was then ligated into pSIF at a ratio of 3:1 and confirmed based on
band sizes following MfellBamHI restriction enzyme digest.

38

Number

Oligonucleotide

1

5' -GGATCCGTGGCGGGTGTGGGGGCCGA-3'

2

5' -GGGGCCGCCCGCCTCTCGGCCCCCACACCCGCCACGGCTC-3'

3

5' -GAGAGGCGGGCGGCCCCGCGGT-3

4

5' -TCACACACGTGCAATGCAACTGCAATGCACCGC-3'

5

5'GCATTGCAGTTGCATTGCACGTGTGTGGGCGGGTGCAGTCCTCG3'

6

5' -CCGGCTCCGGGCTGCACTGCCGAGGCACTGCACCCGCC-3'

7

5' -GCAGTGCAGCCCGGAGCCGGCCCCTGGCACCACGG-3'

8

5' -CAATTGAGGATGGGGGCCCGTGGTGCCAGGGG-3'

9

5' -GTTAACTCCTACCCCCG-3'

Table 1: Oligonucleotide for miR-33b mutant cloning

The pcDNA3-MYC construct was purchased from Addgene (Cambridge, MA). This
construct lacks the MYC 3'UTR but carries the MYC coding region. We then cloned
constructs that either carried the MYC wild-type or mutant 3'UTR. pRL-TK-MYC 3'UTR,
pRL-TK-MYC 3'UTR mutant and pcDNA3-MYC constructs were digested with HindlII
and Xbal to generate desired bands of -500bp (pRL-TK-MYC 3'UTR, pRL-TK-MYC

3' UTR mutant) and 5kb (pcDNA3-MYC ). The ligation experiment was set at 1:3 (insert
to backbone construct) to generate the final pcDNA3-MYC 3'-UTR (MYC 3'UTR) WT
and MYC 3' -UTR mutant constructs.
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All constructs were confirmed by DNA sequencing.

2.2.3. Luciferase assay
E2 promoter binding factor (E2F) was originally identified as a cellular transcription
factor which could bind to and activate the adenovirus E2 promoter (194). E2F activity
appears to playa critical role in cell growth regulation through the activation of a variety
of genes that encode proteins important for DNA replication in S-phase, as well as
various genes that encode cell cycle regulatory proteins that facilitate the transition
through the cell cycle (195, 196). The E2F2 promoter has 4 distinct E-boxes to which cMyc can bind to regulate E2F2 protein expression (197). pSIF, the parental vector for all
our miRNA constructs, served as the control. Renilla luciferase (Rluc) from pRL-TK for
tier-1 and luciferase (Luc) reporters from the pGL3-Promoter for tier-2, are used to
normalize transfection efficiency and total protein synthesis. If a miRNA directly targets
the MYC gene, both LuclRluc of the tier-1 assay and Rluc/luc of the tier-2 assay will be
down-regulated compared to respective controls. However, if a miRNA indirectly downregulates c-Myc, only LuclRluc expression in the tier-1 assay is likely to be reduced. The
success of this strategy depends on: (i) a cell line with a proven record in a specific
pathway; (ii) endogenous miRNA expression levels may dictate how many fold the
exogenous construct can over-produce a specific miRNA, which can be addressed by
comparing levels in cells with or without the miRNA construct, or using antisense to
miRNA to inhibit endogenous expression.

40

We used a two-tier screening assay: tier-l is designed to identify any miRNA that
modulates the c-Myc signaling pathway, and tier-2 is designed to determine which
miRNAs binds the MYC 3 'UTR. In tier-I, we made use of an E2F2-Luciferase construct
(E2F2-Luc). This construct is made up of a luciferase gene whose expression is regulated
by the E2F2 promoter cloned down-stream of the luciferase gene. In this case miRNA
modulation of endogenous c-Myc activity regulates firefly luciferase activity. The given
miRNA can target c-Myc expression by either binding the 3'UTR of MYC or the 3'UTR
of other genes that regulate c-Myc expression. Based on endogenous c-Myc expression,
differential binding to the E2F2 E-box occurs, and this is determined based on the
luciferase reporter measurement. The pRL-TK (renilla luciferase -Rluc) expression
vector is used as an internal control. HEK293T cells (3 x 104 cells/well) were cotransfected in triplicate wells with 80 ng/well of pSIF, or -400 miRNA present in our
miRNA library, 20 ng/well of pRL-TK and 100 ng/well of the E2F2-Luc construct using
the Lipofectamine LTX reagent (Invitrogen, Carlsbad, CA). Luciferase reporter activity
was measured 48 hrs post-transfection using the Dual-Glo Luciferase assay system
(Promega, Madison, WI) as per the manufacturer's instruction. To determine the effect of
a specific miRNA on the c-Myc pathway, the ratio of LuclRluc was calculated. The value
from the vector-transfected wells was normalized to a value of one, and the values from
cells transfected with miRNAs were analyzed in comparison to this. Values lower than
one indicated a negative effect on the c-Myc pathway. Similarly, the Dual Glo Luciferase
assay was used to determine whether mutation of the E2F2 WT construct abrogated the
effects of miRNA targeting. The E2F2-luc mutant construct has mutated bases in two of
the E2F2 promoter E-boxes. These mutations have been shown to significantly affect c-
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Myc activity on the E2F2 promoter resulting in reduced luciferase reporter activity (197).
This mutant construct (lOOng/well) was co-transfected with 80 ng/well of miR-33b, miR33a or pSIF, and 20 ng/well ofpRL-TK vector into 293T cells (3 x 104cells/well) in 96well plates. Dual Glo luciferase assay was performed 48 hrs later. Analysis was
performed as described for the wild type E2F2-luc construct assay.

Tier-2 assay was designed to determine miRNAs that directly bind the 3'UTR of target
genes. In this assay, we used a cloned pRL-TK-MYC 3'UTR-Luc construct and a pGL3Luc construct as a transfection control. In this system, binding of miRNA to the 3' UTR
mediates the down-regulation of Rluc expression. We co-transfected 293T cells (3 x 104
cells/well) in 96-well plates with 120 ng/well ofpRL-TK-MYC-3'-UTR WT, 80 ng/well
of 56 miRNAs (individually) predicted from TargetScan and Miranda to target MYC, and
20 ng/well of pGL3-Luc construct (which act as intemalluciferase control) in triplicate
wells. Dual-Glo Luciferase assay (Promega, Madison, WI) was performed and miRNAs
binding the MYC 3'UTR were determined based on LuclRluc ratio. The value obtained
from vector-transfected wells were normalized to one and the values for the miRNAs
were analyzed in comparison to this, with values lower than one indicating binding to

MYC 3'UTR and negative regulation of MYC. A pRL-TK-MYC-3'UTR mutant construct,
mutated at 4 nucleotides that form complementary base pairs with the miR-33b seed
region, was used to determine whether preventing miR-33b binding at the seed region
4

will abrogate down-regulation of the luciferase reporter. 293T cells (3 x 10 cells/well) in
96-well plates were co-transfected with 120 ng/well of pRL-TK-MYC 3'UTR mutant, 80
ng/well of miR-33b and 20 ng/well of pGL3-Luc construct (intemalluciferase control) in
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triplicate wells, and Dual-Glo Luciferase assay was performed. The data were analyzed
similarly to that of the WT construct.

2.2.4. Western blot analysis
HEK293T cells (lx106cells/well) cultured in 6-well plates were transfected with 2.5 Ilg
of pSIF, miR-33b, and miR-33a or miR-333b mutant. Medulloblastoma cell lines DAOY and D283-Med were stably transfected with pSIF-mKate or miR-33b. Total
protein was extracted using IX RIPA reagent (Cell Signaling Technology, Danvers, MA)
containing IX protease inhibitor cocktail (Sigma, St. Louis, MO). The protein
concentration was determined using the Bicinchoninic Acid (BCA) method (Thermo
scientific, Rockford, IL) according to the manufacturer's protocol. The sample was boiled
with Leammli buffer for 10 mins, fractionated by SDS-polyacrylamide gel
electrophoresis and transferred at 4°C to nitrocellulose membranes. Protein membranes
were incubated in blocking buffer (Ix Tris-buffered saline - TBS, ph 7.5,5% Non-fat
dried milk) for 2 hrs at room temperature. The membranes were incubated over-night at
4°C on a shaker with anti-c-Myc (Santa Cruz, Santa Cruz, CA; sc-40; diluted 1:1000),
anti-Cyc1in E (Santa Cruz, Santa Cruz, CA, ; sc-25303; diluted 1:1000), anti-VEGF-A
(Santa Cruz, Santa Cruz, CA; sc-7269; diluted 1: 1000), anti-Gadd45 (Santa Cruz, Santa
Cruz, CA; sc-6850; diluted 1:1000), anti-ODC (Cell signaling, Danvers, MA: 1:1000) or
~-Actin

(Sigma, St. Louis, MO; AC-15; diluted 1:5000) antibodies. The membranes were

washed 3 times, 10 minutes per wash, with Ix TBS containing 0.05% Tween 20,
incubated with horse peroxidase-linked goat anti-mouse IG antibody (Santa Cruz, Santa
Cruz, CA; sc-2005; 1:5000) or goat anti-rabbit IG antibody (Cell Signaling, Danvers,
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MA) for 1 hr at room temperature, washed 3X for 10 mins, and visualized with the
Supersignal west DuralFemto Chemiluminescent substrate kit (Pierce, Rockford, IL).

c-Myc null cells, H015.19 (2x106 cells/ well) were plated in 6-well plates and cotransfected with 2 ~g pSIF, miR-33b or miR-33a, and 2~g ofpcDNA3.1-MYC-MYC 3'UTR or pcDNA3.1-MYC-MYC 3'-UTR mutant. Total protein was extracted 48 hrs after
transfection and western blot analysis performed to determine c-Myc, and Cyclin E and
~-Actin

expression.

The quantification of protein expression levels was determined by ImageJ
(http://rsb.info.nih.gov/iD with arbitrary units (AU) reflecting the signal density from the
blot.

2.2.5. Quantitative real-Time PCR (qRT-PCR)
TaqMan miRNA assay and gene expression assay (applied Biosystem inc., Forest City,
CA) were used to detect the expression level of mature miRNAs and gene mRNA
expression, respectively (198). U6 RNA and fl-Actin mRNA was used for normalization.
To determine whether miR-33b affects MYC mRNA levels, 293T cells (5x104cells/well),
were plated in 12-well plates and transfected with

l~g

of pSIF, miR-33b, miRNA

inhibitor negative control or antisense miR-33b. Also, D283 and DAOY cells were stably
infected with empty vector or miR-33b. Total RNA was extracted 48 hrs posttransfection by one of two methods: the cells were washed twice with IX PBS,
resuspended in 50 ~l of IX PBS and heated at 95°C for 5 mins; or total RNA was
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extracted using TriZol reagent (Invitrogen, Carlsbad, CA) as per the manufacturer's
protocol. Total RNA concentration was detected by nanodrop. To quantify miR-33b
expression levels, reverse transcription (RT) reaction was performed with 100 ng RNA in
a reaction mixture containing 5x miR-33b and U6 RT primer, IX RT buffer and
0.0125mM DTT. For mRNA expression level, reverse transcription (RT) reaction was
performed with 100 ng RNA using the iScript cDNA synthesis Kit (Bio-RAD, Hercules,
CA) as per the manufacturer's instruction. Reverse transcription conditions were as
follows: 16°C for 30 mins, 42°C for 30 mins and 85°C for 5 mins. The PCR product was
used in a TaqMan PCR miRNA or gene expression assay (ABI, Forest City, CA).
TaqMan 20x probe for miR-33b was used to detect expression levels of miR-33b and
TaqMan 20x probe for MYC was used to detect expression levels of MYC mRNA. U6
RNA or ~-Actin mRNA was used for normalization. Similar experiments were done with
total RNA extracted from MYC null cells H015.l9, co-transfected with; lllg of pSIF,
miR-33b or miR-33a and lllg ofpcDNA-MYC-MYC 3'-UTR WT or pcDNA-MYC-MYC
3' - UTR mutant.

To determine the expression level of stem cell marker genes, TaqMan gene expression
assay was performed from total RNA extracted from neurospheres and differentiated
neurospheres. D283 cells, stably transfected with vector or miR-33b and cultured in
neurobasal media, formed neurospheres that were further differentiated by culturing in
EMEM growth media. Total RNA was extracted from neurospheres or differentiated
neurospheres using TriZol reagent. cDNA was synthesized using the iScript kit and used
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for TaqMan real-time PCR for MELK, MYC, SOX2, CD133 andfJ-Actin mRNA
quantification.

To determine whether c-Myc activates the miR-33b promoter, 293T cells and HeLa cells
(1 x 104 cells/well) were plated in 24-well plates and transfected with 3 ~g of
pcDNA3.1+, or 1,2, or 3 ~g ofpcDNA-MYC, and total RNA extracted after 48hrs. QRTPCR was performed using the TaqMan gene or miRNA expression assay for
quantification of MYC mRNA and miR-33b levels. fJ-Actin and U6 were used as internal
controls.

2.2.6. Cell cycle analysis
D283 and Daoy cells were stably transfected with empty vector or miR-33b. Also, Myc
null cells, H015.19, were co-transfected with vector or miR-33b and pcDNA-MYC
3'UTR or pcDNA-MYC 3'UTR Mut. The various cell types were collected after 48 hrs

and washed twice in IX PBS. Cells were suspended in 1ml of ice-cold 70% ethanol and
kept at 4°C for 24 hrs. The next day, the cells were washed twice with IX PBS and
treated with 1mglml Ribonuclease for 90 mins at 3TC in 0.5 ml of IX PBS. Before cell
cycle analysis, cells were stained with 5~glml of PI and protected from light. Flow
cytometry was performed with a FACScan apparatus. A minimum of 20,000 cells per
sample were collected and the FACS files were further analyzed using FlowJo software
(Tree Star Inc., Ashland, OR) for cell cycle analysis. The excitation wavelength was
488nm, and red fluorescence (>590 nm for PI) was recorded. In addition, the parameters
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for forward scatter (FSC) and side scatter (SSC) were determined. For each variable
(exposure condition, culture period etc.) a minimum of 3 samples were quantified.

2.2.7. Transwell cell migration assay
D283 (lx10 4 cells/well) and Daoy (lx104 cells/well) cells were stably transfected with
1.6 I1g of empty vector or miR-33b, washed twice with IX PBS and resuspended in
serum-free EMEM. Transwell (Boyden) assay was then performed 48 hrs after
transfection. Briefly, Transwell (Boyden) chambers (Invitrogen, Carlsbad, CA), with a
pore size of 811m, were placed into triplicate I2-well plates. EMEM media supplemented
with IO% FBS which served as a chemoattractant was added to wells beneath the
Transwell chamber. D283 cells (lx104 ) or Daoy cells (lxlO\ in 0.5ml of serum-free
EMEM media were added to the Transwell chamber and the plates were then incubated at

3TC in a humidified 5% CO2 atmosphere for 24 hrs. The cells were fixed with methanol
for 10 mins, and stained with 0.4% crystal violet for 2 hrs. Non-migrated cells on the
upper side of the filter were removed with a cotton swab, and the filter mounted on
microscope glass slides. Images were captured using a Nikon Eclipse TE300 microscope
and a Nikon Plan Fluor lOx0.30 objective. The migrated cells were counted using ImageJ
software. D283 and Daoy cells (0.5x104) similarly transfected, were cultured in serum
free media, and 24hrs later MTT cell proliferation assay performed.

2.2.8. Neurosphere assay
The neurosphere assay has proven to be an excellent technique to isolate neural stem cells
and progenitor cells to investigate the differentiation and potential of cell lineages.
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Medulloblastoma is believed to have a stern cell origin; therefore we reasoned that
growth of medulloblastoma cells in media that favors neural stern cell growth will result
in neurosphere formation. D283 cells (1 x 106) were stably transfected with empty vector
or miR-33b and neurosphere assay performed. Briefly, the cells were trypsinized,
washed in neurobasal medium (Invitrogen, Carlsbad, CA) and resuspended in Matrigel4

coated plates at 5x10 cells/ml in the neurobasal medium containing 2rnM L-glutamine,
N2 supplement, B27 supplement, 20ng/ml hrEGF, 20ng/ml hrbFGF and 50)lg/ml BSA
(Invitrogen, Carlsbad, CA). The growth factors, 20ng/ml hrEGF and 20ng/ml hrbFGF,
were added daily to the plates and the neurobasal medium were replaced twice per week
with fresh neurobasal media. After lOdays of incubation, primary neurospheres were
disaggregated into single-cell suspensions and reseeded to form secondary, tertiary and
quaternary spheres in 96-well plates. Spheres larger than 50)lm in diameter were counted
by microscopy (magnification, lOX) and quantified.

2.2.9. Soft agar colony formation (clonogenic) assay
Clonogenic assay or colony formation assay is an In Vitro cell survival assay based on
the ability of a single cell to grow into a colony. The assay essentially tests every cell in
the population for its ability to undergo "unlimited" division. The effect of miR-33b overexpression on colony formation ability of D283 cells was assessed by soft agar colony
formation assay. Medulloblastoma D283 cells were stably transfected with empty vector
or miR-33b. The cells were collected in fresh EMEM media after 48hrs and incubated in
soft-agar. The soft agar plate contains a bottom layer of 0.5% agar and a top layer of
0.2% agar. Approximately 2000, appropriately transfected, D283 cells were plated over
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the top layer of a 6-well plate. The cells were maintained at 3TC in a humidified 5% CO 2
atmosphere for two weeks. Fresh media was added at regular intervals to prevent the
plates from drying out. At the end of two weeks, the cells were treated with 0.5% of MTT
reagent for 2-3 hrs. Colony sizes were assessed after imaging using a scanner or
microscopy (original magnification, x4).

2.2.10. Orthotopic tumor formation
All animal experiments were conducted according to a protocol approved by the
University of Louisville Animal Care and Use Committee (IACUC number 08107). D283
cells (1 x 106cells/well) in 6 well plates were stably transfected with vector or miR-33b.
Positive transfection was checked by visualization of red fluorescent protein (RFP)
expressed by the vector and, positive transfectant were selected with 400f..lglml of G418
(Cellgro). Recipient immunodeficient nude mice were purchased from Taconic (C.B-Igh1b/IcrTac-Prkdcscid ; FOX CHASE CB-17 SCID ICR; Taconic). Male 9- to 12-week old
mice were anesthetized with rapid-sequence inhalation isofluorane (Abbot Laboratories,
Abbott Park, IL). lO-mm skin incision was made along the midline of the head and a
1mm burr-hole was drilled into the skull and a total of 1x105 cells expressing the empty
vector or miR-33b were orthotopically injected into the cerebellum of each
immunodeficient nude mouse. The mice were monitored for any sign of distress and
maintained for 6 weeks in the animal housing facility at the University of Louisville. The
mice were sacrificed 6 weeks later and fixed in 10% formalin for 3 days. After fixation,
the brains were embedded in paraffin and 5 f..lm thick sections were made following
routine procedure.
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H&E staining was performed to determine size and location of tumors formed by D283
cells either expressing empty vector or miR-33b. Briefly, the tissue sections were
deparafinized by incubating twice in xylene for 10 mins per incubation. The sections
were then rehydrated by incubating twice for 5 mins in 100% ethanol, then for 2 mins
each in 95% and 70% ethanol. The section was then washed with copious amounts of
distilled water and stained by incubating in Harris hematoxylin (Sigma, St. Louis, MO)
solution for 10 mins, followed by washing with tap water for at least 5 mins. The sections
were then differentiated by incubating in 1% ethanol for 30 seconds and washed with tap
water for 2 mins. The sections were then washed and rinsed in 90% ethanol and counterstained in eosin-phloxine (Sigma, St. Louis, MO) solution for 0.5-1 min. After the
staining the section were dehydrated by incubating twice in 95% ethanol for 5 mins per
incubation and 2 changes of xylene for 5 min per change. The sections, from comparison
brain location, were then mounted on the microscope using xylene based mounting
medium. Images of the tumors or whole brain were taken using a microscope
(magnification 20X, 100X, 200X and 400X). Tumor surface area was determined using
the Olympus microscope.

2.2.11. Immunohistochemistry (IHC)
Immunohistochemistry was performed according to the avidin biotin complex (ABC)
peroxidase method using Rabbit and Mouse IgG ABC Elite1 detection kits (Vector
Laboratories, Burlingame, CA). Prior to the performance of the immunohistochemical
procedure, 5 !lm thick histological sections from paraffin-embedded tissue blocks were
subjected to non-enzymatic antigen unmasking in 0.01M sodium citrate buffer (pH 6.0)
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for 10 min in a microwave at medium power. The rabbit polyclonal antibody against cMyc (Santa Cruz; SC-789; Dilution 1:500), rabbit monoclonal antibody against Sox2
(Cell signaling; D6D9; Dilution 1:500), rabbit monoclonal antibody PC 10 to PCNA (Cell
Signaling; PClO: Dilution 1:100), and rabbit monoclonal antibody against Cyclin E
(Abcam; ab7959: Dilution 1: 100) were used to determine protein expression. Briefly,
tumor sections on slides were deparaffinized by incubating in HD 1 and HD2 solution for
10 mins per solution. This was followed by re-hydration by incubating at: 100%, 95%,
80%, and 70% ethanol for 5 mins per solution, followed by 5 min incubation in lXPBS.
The slides were then washed copiously with dH20. The tumor sections were incubated
with a proteinase K for 5 mins and peroxidase block solution for 15 mins at room
temperature. Primary antibody against c-Myc, Sox2 or PCNA was added and the slides
were incubated overnight at 4°C. The slides were then washed three times with IX PBS
and incubated with secondary anti-rabbit-HRP antibody for 1.5 hrs. The slides were then
washed three times with IX PBS at 10 mins per wash. This was followed by chemical
reaction of the horse radish peroxidase (HRP) attached to secondary antibody by
incubating tissue sections in HRP DAB substrate buffer, followed by counter staining
with methyl green or hematoxylin solution. The slides were then washed in dH20. The
tumor samples were then dehydrated by incubation for 5 mins each in 70%,80%,95%
and 100% ethanol and the HD 1 and 2 solutions for 10 mins each. Tumor slides were
imaged by microscopy (magnification, 20X, 40X, 100X, 200X and 400X). The tumor
images were scored on a scale of 0 to 3 (3 indicating strong expression, 2 moderate
expression, 1 medium expression, 0 no expression) by three independent scorers.

51

2.2.12. Statistics
The experimental results were expressed as the mean ± standard deviation of at least 3
independent experiments. Two-tail Student's t-test was performed with p:SO.05 (*)
considered as statistically significant between the samples and their respective controls.

2.3. RESULTS
2.3.1. MicroRNAs targetMYC 3'-UTR
We used reporter assays to screen miRNAs for their ability to modulate c-Myc
transcriptional function and target MYC 3'UTR directly (Fig. 3). In Assay 1, a firefly
luciferase gene (luc) is driven by the promoter to E2F2 (E2F2-luc), which is regulated by
c-Myc (197). miRNAs-of-interest, E2F2-luc, and a Renilla luciferase (Rluc) construct
constitutively expressing Rluc are co-introduced into 293T cells to screen miRNAs that
down-regulate the reporter luc. In Assay 2, we cloned the 3'UTR of MYC downstream of
the Rluc construct and co-expressed it with a respective miRNA and a constitutively
expressed luc to determine whether the miRNA targets the MYC 3'UTR to down-regulate

Rluc.
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Fig. 3:

The 2 tier luciferase screening method. (A) Assay 1 is designed to identify
miRNA that functions in the c-Myc pathway and can either target the 3 'UTR of
MYC or the 3 'UTR of another gene that regulate c-Myc activity. (B) Assay 2 is

designed to identify miRNAs that directly target the 3 'UTR of MYC. The MYC
3 'UTR ofMyc is cloned down-stream of a renila (Rluc) gene and binding of the

miRNA to the 3 'UTR down-regulates the luciferase activity from RIuc.
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We performed Assay 1 in 293T cells using hundreds of miRNA minigenes in our genetic
library (199) and found that 4 miRNAs (miR-33a, miR-33b, miR-212, miR-203)
significantly down-regulated the c-Myc-dependent reporter, while miR-21O up-regulated
it (Fig. 4A). Next, we performed Assay 2 using 54 miRNAs that were predicted to target

MYC and found that miR-33b and miR-203 down-regulated the reporter with MYC
3'UTR downstream (Fig. 4B). Our results with miR-21O suggested that it did not target
the 3'UTR of MYC, but up-regulated c-Myc-dependent luc expression, which is
consistent with a recent study demonstrating that miR-21O targets MNT, an antagonist of
c-Myc (200). To determine whether MYC is a bonafide miR-33b target gene, we
performed Assay 1 using a mutant E2F2-luc construct, in which 2 of its 4 E-boxes (cMyc binding sites) were disrupted (197). As expected, the expression of luc was
significantly reduced (-10 fold) when E-boxes on the promoter were perturbed (Fig. 5A).
The regulation of luc by miR-33b was abolished with the removal of 2 E-boxes (Fig. 5A).
When a MYC 3'UTR mutation construct (Fig. 5B) that disrupts miR-33b binding to the
'seed' sequence of miR-33b was used in Assay 2, we found that the down-regulation of

Rluc by miR-33b was abrogated (Fig. 5B). Our results verified that miR-33b is a
negative regulator of c-Myc through directly targeting MYC 3'UTR.
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miR-33b is a negative regulator of c-Myc directly targeting the MYC

3'UTR. (A) Luciferase assay from an E2F2-luciferase construct. The Luciferase
activity is under the control of the E2F2 promoter that contains 4 c-Myc binding
E-boxes. Values below the RLU ofthe vector (normalized to 1) indicate downregulation of luciferase activity. (B) RIuc assay from a Myc 3 'UTR cloned
upstream of the renilla luciferase gene. Values below the RLU of the vector
(normalized to 1) indicate down-regulation of luciferase activity.
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assay from E2F2-Luciferase mutant construct. Two c-Myc binding E-Boxes are
mutated. (B) Luciferase assay from a MYC 3'UTR mutant construct (Right).
Mutant construct containing four nuc1eotides substitution at the miR-33b ' seed'
binding site on MYC 3 'UTR (Left).
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2.3.2. Over-expression of miR-33b in 293T, Daoy and D283 cells down-regulates

MYC mRNA expression
We used TaqMan miRNA and gene expression assays to determine which possibility is
favored by miR-33b on MYC mRNA. In the scenario where a miRNA leads to mRNA
translational repression, the steady state level of mRNA in the cell will remain unchanged
despite down-regulation of protein expression, whereas if the miRNA leads to cleavage
of the mRNA, down-regulation of the target gene's mRNA will be observed. Following
transfection of miR-33b into 293T, D283 and Daoy cells, total RNA was extracted and
used for TaqMan qRT-PCR. The miR-33b expression was increased by more than 10 fold
following over-expression compared to the parental vector control. The steady state
levels of MYC mRNA were significantly reduced with miR-33b over-expression in 293T
(Fig. 6A), D283 (Fig. 6B) and Daoy cells (Fig. 6C), suggesting that mRNA degradation
likely contributed to miR-33b-mediated MYC suppression.
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2.3.3. miR-33b down-regulates the expression of c-Myc protein and its
transactivational function in 293T cells
To determine whether miR-33b expression result in down-regulation of c-Myc protein
expression, we over-expressed miR-33b and performed western blot analysis. We
transfected increasing amounts of miR-33b expression constructs (0, 1,2 and 3 Ilg) into
293T cells in 6-well plates and found that over-expression of miR-33b down-regulated cMyc protein levels in a concentration-dependent manner (Fig. 7A). We did not pursue
miR-203 as it did not reduce c-Myc protein levels (Fig. 7A). In subsequent experiments,
except when stated, we use 2 Ilg of miR-33b expression plasmid to avoid a significant
reduction of cell proliferation and unwanted cell death. We noted that miR-33b but not
miR-33a down-regulated c-Myc expression (Fig. 4B), although miR-33a differs from
miR-33b by only two nucleotides (UA compared to CG respectively) on position 9 and
10 of their mature sequences (Fig. 7B). We constructed a mutant miR-33b (miR-33bM)
whose mature sequence resembled miR-33a (Fig. 7B). Over-expression of miR-33b but
not miR-33a or miR-33bM reduced the protein levels of c-Myc, as well as two known cMyc transactivational targets: Cyclin E and ornithine decarboxylase (ODC); while
Gadd45u, a c-Myc-repressed target was up-regulated (Fig. 7C). The miR-33b binding
site is present in MYC 3 'UTRs from human, chimpanzee, and rhesus, but not those from
mouse, rat, dog, and other mammals (Fig. 8A) and miR-33b is only present in primates
(201), suggesting that miR-33b is a primate-specific regulator of c-Myc. Overexpression of an exogenous MYC gene in 293T cells did not increase the expression
levels of miR-33b (Fig. 8B), indicating that miR-33b expression is not regulated by cMyc.
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Over-expression of miR-33b in 293T cells down-regulates c-Myc and its
target genes. (A) Western blot analysis for expression of c-Myc in 293T cells
transfected with increasing concentration of miR-33b. miR-203 did not affect cMyc protein expression (B) Schematic representation of the binding of miR-33b,
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2.3.4. miR-33b down-regulates exogenously expressed c-Myc in MYC-null H015.19
cells
To further validate that miR-33b specifically targets MYC, we introduced two c-Myc
constructs into a MYC-null cell line H015.19 (202): both have a native c-Myc coding
sequence but one with a wild-type 3' UTR (3' UTR WT) and the other with a mutant

3'UTR, in which the miR-33b binding site was disrupted (3'UTR Mut). As shown in Fig.
9A, miR-33b down-regulated the expression of c-Myc and Cyc1in E in cells with 3'UTR
WT but not in those with 3'UTR Mut. The changes of MYC mRNA levels showed similar
patterns to that of the protein levels (Fig. 9B). miR-33b led to more Gl arrest in cells
carrying MYC with 3' UTR WT compared to that with 3' UTR Mut (Fig. 9C). These
results show that miR-33b regulation of c-Myc expression and function is dependent on
the 3' UTR of MYC mRNA.
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miR-33b down-regulates exogenously expressed c-Myc in MYC-null
H015.19 cells. (A) Western blot analysis show that miR-33b down-regulates
exogenously expressed c-Myc from a MYC construct with the 3 'UTR WT, but
not a 3 'UTR mut, and c-Myc transcriptional target Cyclin E. (B) qRT-PCR
demonstrates a reduction in MYC mRNA level following miR-33b overexpression. (C) Flow cytometry analysis for cell cycle progression of MYC-null
cells following over-expression ofmiR-33b On the left is a representative photo
of a single flow cytometry run with the y-axis donating events (number of cells)
and the x-axis donating the emitted fluorescent of the DNA dye (PI): the bar
graft on the right is provided to summarize three independent runs.
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2.3.5. Re-introduction of miR-33b in D283 cells down-regulates c-Myc and adversely
affects its functions.
The human miR-33b gene is located in intron 17 of SREBF1-miR-33b gene and their
genomic locus 17p11.2 is frequently lost in medulloblastoma. c-Myc is over-expressed in
-31-64% of medulloblastoma, yet MYC amplification only accounts for -5-15% of cases
(96). We hypothesize that miR-33b loss is responsible for c-Myc over expression, in
medulloblastoma. We first employed D283, a medulloblastoma cell line without 17p11.2
with no MYC gene amplification, yet with high levels of c-Myc (203). When miR-33b
was reintroduced, c-Myc expression was down-regulated, along with its transactivation
targets Cyc1in E and ODC, and Gadd45a (a c-Myc repressed target) was up-regulated
(Fig. lOA). Coinciding with down-regulation of Cyc1in E, more cells arrested at the G 1
phase when miR-33b was over-expressed in D283 cells (Fig. lOB). The role played by cMyc in inducing cell proliferation and apoptosis is partly due to its ability to up-regulate
ODC and Gadd45a expression, respectively. Over-expression of miR-33b resulted in
reduction in MTT -assayed cell proliferation compared to empty vector alone (Fig. 11A).
To verify whether the reduction in cell proliferation by miR-33b is dependent on MYC
3'UTR, D283 cells were transfect with a MYC-expressing construct carrying either
3'UTR WT or 3'UTR Mut, in which the miR-33b binding site was disrupted
(3'UTRMut). As miR-33b targets 3'UTRWT but not 3'UTRMut, cell proliferation was
reduced only in cells carrying MYC with the 3'UTRWT (Fig. lIB). We also found miR33b reintroduction down-regulated the expression of miR-9, a miRNA regulated by cM yc (204) that mediates cell migration (Fig. 11 C) and resulted in a reduction in cell
migration (Fig. lID).
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Collectively, these data support that reintroduction of miR-33b into miR-33b-null D283
cells caused down-regulation of c-Myc and its transcriptional targets, decreased cell
proliferation, cell cycle progression, and cell migration.
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panel is the bar graph summarizing three independent experiments.
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2.3.6. Stem cell characteristics of D28 cells are abrogated by miR·33b
Medulloblastoma is a tumor which is characterized by an undifferentiated stem- or
progenitor-like appearance in the majority of its cells with neurons, and glia cell types
detected. c-Myc is a major player in the maintenance of stem cell self-renewal (88, 205)
and appears to playa crucial role in medulloblastoma development. Medulloblastomas
have been reported to have a stem cell origin and are capable of forming neurospheres
when incubated in neurobasal medium (206, 207). Even in regular growth medium, there
is a major morphological change (multicell aggregates to desegregated single cell
suspension) in D283 cells stably transfected with miR-33b (Fig. 12A). When cultured in
neurobasal medium, D283 cells with miR-33b formed fewer neurospheres compared to
the control (Fig. 12B). In neurobasal medium, the mRNA levels of MYC and two stem
cell markers SOX2 and CD133 was reduced with miR-33b overexpression, while in
growth medium, miR-33b introduction resulted in decreased expression of SOX2 and
MYC but not that of CD133 (Fig. 12C). We also determined the expression of a neural
stem cell marker Musashi, a RNA-binding protein that is essential for neurosphere
formation and proliferation(208-21O). miR-33b-expressing D283 neurospheres had
lower levels of Musashi, while Musashi expression was not altered significantly when
cells were cultured in growth medium (Fig. 12D). These results show that miR-33b
expression is sufficient to activate differentiation of medulloblastoma cells via c-Myc
down-regulation. Furthermore, miR-33b over-expression results in the negative
regulation of stem cell characteristics of medulloblastoma cell line.
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Fig. 12: Stem cell characteristics of D283 cells are adversely affected by miR-33b.
(A) Morphological change of D283 cells with stable expression of miR-33b in
growth medium. (B) Neurosphere formation assay of D283 cells stably
transfected with parental vector or miR-33b. MiR-33b is impaired in neurobasal
medium. The top panel donates a representative photo of primary and
secondary neurospheres; the bottom panel is a bar graph summarizing three
independent experiments (C) QRT-PCR for the mRNA levels of the stem cell
markers MELK, MYC, Sox2 and CD133 from RNA extracted from Neurosphere
or differentiated neurosphere. (D) Immunocytometry to determine the levels of
musashi in stably transfected vector or miR-33b D283 neurospheres or
differentiated neurospheres.MmiR-33b expression results in reduced expression
of Musashi in neurospheres.
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2.3.7. Over-expression of miR-33b in Daoy cells down-regulates c-Myc and adversely
affects c-Myc-mediated cellular function
We used a medulloblastoma cell line, Daoy, with intact SREBF1-miR-33b gene to
determine whether over-expression of miR-33b will negatively affect medulloblastoma
development. Daoy medulloblastoma cells are adherent cells and, unlike D283 cells, have
a 'glial' phenotypic profile. Daoy are desmoblastic in origin and exhibit a less aggressive
characteristic compared to the metastatically derived D283 cell line. Over-expression of
miR-33b resulted in down-regulation of the protein levels of c-Myc and its targets Cyclin
E and ODC (Fig. 13A). Gadd45u, a protein repressed by c-Myc, was up regulated (Fig.
13A). Over-expression of miR-33b in Daoy cells resulted in delay at G 1cell cycle (Fig.
13B) and decreased cell proliferation (Fig. 14A). Finally, the expression of miR-9 was
decreased (Fig. 14B) and cell migration was significantly reduced when miR-33b was
over expressed in Daoy cells (Fig. 14C).

These results demonstrate that miR-33b has similar effects on miR-33b-negative
medulloblastoma cells and miR-33b-positive medulloblastoma. Therefore miR-33b is an
attractive chemotherapeutic target against medulloblastoma.

71

A
e-Mye
eyelin E

Fig. 13: Over-expression of miR-33b in Daoy cells down-regulates c-Myc and
increase Gl cell cycle arrest. (A) Western blot analysis for protein levels of cMyc and its transcriptional targets Cyc1in E and ODC in Daoy cells transfected
with vector or miR-33b. (B) Flow cytometry analysis to determine cell cycle
progression of Daoy cells transfected with the parental vector or miR-33b. On
the left is a representative photo of a single flow cytometry run with the y-axis
denoting events (the number of cells) and the x-axis denoting the emitted
fluorescence of the DNA dye (PI); a bar graph on the right is provided to
summarize three independent runs.
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2.3.8. miR-33b expression reduces tumorigenesis of D283 cells
The soft agar colony forming ability of D283 cells was tested following stable
transfection with either a vector control or miR-33b. D283 cells expressing miR-33b
formed significantly less colonies on soft agar compared to D283 cells stably transfected
with parental vector (Fig. 15). We then injected D283 cells constitutively expressing
miR-33b or vector orthotopically into the cerebellum of immunodeficient nude (nu/nu)
mice. Six weeks following injection, there was significantly less tumor expansion in brain
ventricles of mice injected with cells carrying miR-33b compared to cells stably
transfected with the parental vector (Fig 16A). As miR-33b is shown to down-regulate cMyc expression, we performed immunohistochemistry (IRC) on tumor sections to
determine the expression level of c-Myc, Cyclin E, and sox2 proteins. miR-33bexpressing D283 tumors expressed less c-Myc, Cyclin E and Sox2 compared to the
control (Fig. 16B). Taken together, we conclude that miR-33b decreases
medulloblastoma tumor growth via c-Myc-mediated inhibition of cell cycle progression
as evident by lower levels of c-Myc and Cyclin E.
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Fig. 16: miR-33b reintroduction in D283 cells reduces tumorigenicity. (A)
Hematoxylin Eosin (H&E) staining of mouse brain injected with D283 cells
stably transfected with vector or miR-33b. Tumors are light blue; red dot
donates blot vessels within tumors. (B) IHC ofD283 tumors from D283 cells
stably transfected with the parental vector or miR-33b for the expression of cMyc, Cyc1in E and Sox2. Protein expression range is from brownish (high
expression) to light blue (no expression).
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2.4. DISCUSSION
MYC codes for c-Myc, a transcription factor that regulates the expression of up to one

third of human genes (185, 186). The genes regulated by c-Myc have placed it at the
center of many biological processes, including apoptosis, cell cycle, differentiation and
cellular proliferation (96, 211-215). It is now well established that c-Myc expression is
essential for stern cell biology and inhibits differentiation of cells while favoring
proliferation. The importance of c-Myc in carcinogenesis is also supported in animal
models (216). c-Myc is viewed as an attractive target against cancer due to its crucial role
in tumorigenesis. Despite early promise shown by drugs developed to target c-Myc,
complete success is hampered by the lack of a good compound that inhibits c-Myc and
low specificity of current chemotherapeutics against MYC. Therefore, understanding how
Myc is regulated at all levels is critical for a more specific targeted therapy to be
developed. The major goals of this work aimed at studying and identifying miRNAs that
target MYC and how these miRNAs contribute to cancer development. We used a 2-tier
luciferase screening method to systematically identify miRNAs that target the MYC
gene. In tier-I, we made use of the c-Myc binding E2F2 promoter upstream of a
luciferase gene. This enabled us to evaluate miRNAs that affected the MYC pathway. In
tier-2, we cloned the 3'UTR of MYC downstream of a Rluc gene to evaluate which
miRNAs directly target the 3'UTR of MYC. Using these E2F2-luc and MYC 3'UTRbased Rluc constructs we screened 400 and 54 miRNAs, respectively, and showed that
more than 25% of the miRNAs in each group adversely regulated MYC. Our luciferase
results suggest that various miRNAs affect MYC directly as well as other components of
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the MYC pathway. This result serves as a first step in elucidating miRNA targets in the
MYC pathway.

Using miR-210 as a control, we confirmed that our luciferase data are reliable since miR210 up-regulated the reporter assay from the E2F2-luc construct, consistent with a
previous study showing that miR-21O targeted a c-Myc antagonist, MNT, to activate cMyc (217). Also, Let-7a and the miR-17-92 cluster of miRNAs target the MYC gene as
reported previously (218, 219) and this is consistent with our luciferase data which
showed that let-7a and members of the miR-17-92 cluster down-regulate the luciferase
activity of both the E2F2-Luc and MYC 3'UTR based constructs. Our luciferase data
suggest that miR-33b and miR-203 negatively regulated the luciferase reporter from the
E2F2 promoter and the 3'UTR based constructs. However, only miR-33b over-expression
resulted in down-regulation of c-Myc protein levels and this corresponded with decreased
levels of c-Myc targets, Cyclin E and ODe. Also, we demonstrated an up regulation of
Gadd45u, a gene that is repressed by c-Myc. The mRNA-miRNA binding usually results
in either translational repression or mRNA degradation. Translational repression was
believed to be the dominant mechanism observed for the majority of human miRNAs
since perfect complementarity is hardly encountered (220). This observation are
particularly true for mRNAs that have mUltiple binding sites to a given miRNA (220).
However, when the miRNA has just one binding site to the mRNA's 3' UTR, speedy
mRNA degradation is favored (220). We used qRT-PCR assay to reveal that miR-33b
over-expression leads to lower steady state levels of MYC mRNA, favoring a mRNA
degradation mechanism for this pair.
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Other mechanisms likely contribute to c-Myc over-expression in medulloblastoma, as cMyc is over-expressed in -31-64% of cases (221-226), but the MYC gene is amplified in
only 5-15% (94,99, 100). We show that miR-33b, a miRNA whose gene locus on
chromosome 17p11.2 is characterized to be a major breakpoint in a subset (-17%) of
medulloblastoma, regulates c-Myc expression and is sufficient to decrease
medulloblastoma development via reduced cell proliferation, increased G 1 cell cycle
arrest and decrease cell migration. Similar experiments were performed on a
desmoplastic medulloblastoma cell line, Daoy, with similar results. Unlike the anaplastic
D283 medulloblastoma cells which are characterized by loss of chromosome 17p 11.2 and
over-expression of c-Myc (227, 228), the desmoplastic Daoy cells have an intact
chromosome 17p11.2 locus and express miR-33b. This suggests that loss of miR-33b
expression is a contributing factor to aggressiveness of tumor cell growth. Our data show
that expression of miR-33b decreases tumorigenic properties such as proliferation, cell
migration and cell cycle progression. Colony formation assays on soft agar show that
miR-33b was able to reduce the number of D283 colonies compared to empty vector
control.

Medulloblastoma has been reported to have a stem cell origin (229). Medulloblastoma
cells differentiate into numerous cell types, lending credence to its stem-like character.
Furthermore, a group of cancer cells with the ability to self-renew and differentiate into
all cell types continue to gain ground as the major culprit in tumor therapeutic resistance
(230, 231). Development of therapies that could result in targeting the differentiated and
the self-renewing cancer cells will significantly reduce relapses. We used D283 cells to
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determine whether miR-33b expression will affect the stem cell characteristics of
medulloblastoma. We show that stable re-introduction of miR-33b resulted in a
morphological change in the D283 cells, from a multicell aggregate characteristic of stem
cell to desegregated single-cell suspension characteristic of differentiated cells. miR-33bexpressing D283 cells when placed in the neurobasal media that favors the growth of
neural stem cells, formed smaller and lower number of neurospheres compared to the
control. Expression of stem cell markers, MYC, SOX2, CD133, and Musashi was
significantly reduced in miR-33b-expressing neurospheres and differentiated
neurospheres compared to cells stably transfected with the parental vector. These results
suggest that miR-33b targets both the differentiated cancer cells and the self renewing
cells. To replicate our findings in vivo, D283 cells with stable expression of miR-33b or
parental vector using lentivirus infection was injected into the cerebellum of
immunodeficient nude mice to determine whether tumorigenesis is affected. miR-33bexpressing D283 cells formed smaller tumors compared to D283 tumors from cells stably
transfected with the parental vector. Expression levels of c-Myc, Cyclin E and Sox2 was
down-regulated from D283 tumors expressing miR-33b. Differential expression of Cyclin
E indicated that miR-33b acted as a cell cycle regulatory miRNA and functions through a
c-Myc-mediated arrest in cell growth.

In summary, data from these experiments suggest that miR-33b is a negative regulator of
c-Myc, and its loss in a subset of medulloblastomas may contribute to c-Myc over
production and tumor growth.
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CHAPTER 3
A STATIN-REGULATED MICRORNA REPRESSES C-MYC EXPRESSION AND
FUNCTION
3.1. INTRODUCTION
RNA interference (siRNA) technology show great promise based on studies in
mammalian cell-culture systems and animal in vivo models and is currently being
extensively evaluated as a potential therapeutic strategy. The induction of immune
response by siRNA (232) is a drawback of siRNA technology, as well as an observed
increase in mortality, probably due to saturation of the miRNA-processing system.
However, the valuable experience and the knowledge gained from siRNA-based therapy
are used while design miRNA-based technologies. The rationale for using miRNAs as
potential therapeutic targets is based on: (1) miRNAs are endogenous antisense
regulatory molecules; (2) miRNA expression profiles can be used to diagnose disease
states, and deregulated miRNAs contribute to the initiation and development of disease;
(3) mouse models demonstrate that miRNAs play an important role in diseases; (4)
miRNA expression levels respond to physiological stimuli; (5) miRNA expression
profiles change when cells are treated with drugs in vitro; and (6) their small size (23-24
nucleotides in length) makes them attractive for drug development. miRNAs are related
to and function similarly to siRNA (233, 234), which was first identified by Fire et al.
(235). Various miRNA-based therapies including anti-sense miRNAs (236), locked
nucleic acid (234), antagomirs (237), virus vector expressing miRNA (232) and mimic
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miRNAs (156) have been examined, with limited success. Many difficulties are
encountered when considering miRNAs as therapeutic drugs including (1) the extensive
number of targets one miRNA can regulate, (2) delivery to the disease site; (3) lack of
tissue specificity; (4) the potential of the body eliciting an immune response against
them; and (5) low stability in vivo since they may be degraded by endogenous RNases.
Improving the stability of miRNA-based drugs is the major focus of drug design.
Furthermore, to develop effective delivery systems, it is important to gain an in-depth
understanding of cellular miRNA uptake, distribution and the biological activity at
whole-body, organ, and cellular levels. To circumvent these difficulties, repurposing
FDA-approved drugs is a more realistic proposition. Various studies have indicated
differential miRNA expression profiles upon treatment of cells with various compounds
(238, 239). For example, breast cancer cells resistant to doxorubicin (DOX) exhibit a
pronounced deregulation of miRNA expression and altered expression of miRNA
processing enzymes (238). It is therefore possible to modulate specific miRNA
production with approved FDA compounds. However, two drawbacks must be
considered: (1) validation of positive proof-of-concept clinical data for the repurposed
compounds; (2) the ability of the drug to be delivered to the diseased site.

Drug repurposing (also known as Drug re-profiling, Therapeutic Switching and Drug retasking) refers to the development of existing drugs for new indications. These drugs may
have (i) known therapeutic uses, (ii) failed to show efficacy in late stage clinical trials,
without safety issues; (iii) stalled in development for commercial reasons; (iv) passed the
point of patent expiry; or (v) are being explored in new geographical markets (240).
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U sing drug repositioning, pharmaceutical companies have achieved a number of
successes, for example Pfizer's Viagra in erectile dysfunction and Celgene's thelidomide
in severe erythema nodosum leprosum (240). We hypothesize that drug repurposing via
modulation of miR-33b expression will decrease proliferation of miR-33b-positive
medulloblastoma cells.

We used a miR-33b-positive medulloblastoma cell line to screen drugs in the NIH
collection that up-regulated miR-33b and reduced cell proliferation, and specifically
singled out lovastatin. We showed that lovastatin results in a reduction in cell
proliferation of miR-33b-positive Daoy cells, an effect not significant in miR-33bnegative D283 cells. The lovastatin-induced inhibition of Daoy cell proliferation
correlated with an increase in miR-33b expression as well as a down-regulation of c-Myc
expression. Also, Daoy tumor growth was significantly reduced in mice treated with
lovastatin, and tumors expressed lower levels of miR-9, c-Myc and Cyclin E. Treatment
with lovastatin and the methylation inhibitor 5-Azacytidine, which released methylation
of the SREBFl-miR-33b promoter, increased sensitivity to lovastatin in HeLa cells, a cell
line that showed reduced lovastatin sensitivity, via miR-33b up-regulation.

3.2. MATERIALS AND METHODS
3.2.1. Cell culture
Medulloblastoma cells, D283 and DAOY, were purchased from ATCC and cultured in
EMEM (Gibco, Carlsbad, CA) supplemented with 10% FBS and 0.1 % (v/v) AntibioticAntimycotic (Cellgro, Manassas, VA). UW228 medulloblastoma cell line was the kind
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gift of Dr. J.R. Silber (University of Washington, Seattle, WA) and were maintained in
DMEMlF12 supplemented with 10% FBS and 0.1 % (v/v) antibiotic-Antimycotic
(Cellgro, Manassas, VA). The human cervix carcinoma cell line (HeLa cells) was
purchased from ATCC and cultured in DMEM (Gibco, Carlsbad, CA) supplemented with
10% FBS and 0.1 % (v/v) Antibiotic-Antimycotic (Cellgro, Manassas, VA). All cell lines
were cultured at 37°C in an atmosphere containing 5% C02. Transient and stable
transfections were performed as previously described.

3.2.2. Luciferase assay
The LightSwitch Luciferase Assay Kit (SwitchGear, Menlo Park, CA) was used to
determine whether lovastatin activates the SREBF1 promoter. The SREBF1 promoter was
cloned upstream of a Rluc gene. Daoy and D283-Med cells in 96-well plates were
transfected with the SREBFl-luc promoter construct (SwitchGear Genomics, Menlo
Park, CA), an LDHA-PROM positive control (SwitchGear, Menlo Park, CA) and a
negative control ROl-PROM (SwitchGear, Menlo Park, CA) in triplicate wells. The cells
were treated 24 hrs following transfection with 0, 0.2, 2 or 10 ~M of lovastatin.
Luciferase activity was measured 24 hrs later, using the LightSwitch Luciferase Assay
Kit, per the manufacturer's instruction. Briefly,

100~1

of the assay solution, made-up of

Ix substrate in assay buffer, was pippeted into each well and incubated in the dark for 30
mins, followed by luciferase reporter measurement. Luciferase activity was normalized
against values of the positive and negative control.

3.2.3. Western blot analysis
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Medulloblastoma cell lines D283, Daoy and UW228 (1 x 106cells/well) cultured in 6well plates were treated with lovastatin (0, 0.2, 2, 10 11M) and total protein was extracted
using 1X RIPA reagent (Cell Signaling Technology, Danvers, MA) containing 1X
protease inhibitor cocktail (Sigma, St. Louis, MO) after 48 hrs. Total protein
concentration was determined using the Bicinchoninic Acid (BCA) method (Thermo
scientific, Rockford, IL) according to the manufacturer's protocol. Western blot for cMyc (Santa Cruz, Santa Cruz, CA; sc-40; diluted 1: 1000), Cyclin E (Santa Cruz, Santa
Cruz, CA; sc-25303; diluted 1:1000), Gadd45a (Santa Cruz, Santa Cruz, CA; sc-6850;
diluted 1:1000), ODC (Cell signaling; Danvers, MA; dilution 1:1000) and

~-Actin

(Sigma, St. Louis, MO; AC-15; diluted 1:5000) expression was performed. HeLa cells in
6 well plates were treated with lovastatin (0, 0.2, 2, 10 11M) or lovastatin (0.2 11M), 5Azacytidine (0.2 11M) or lovastatin (0.2 IlM)/5-azacytidine (0.2 11M) for 48 hrs. Total
protein from treated cells was used for western blot analysis for c-Myc, Cyclin E, ODC,
Gadd45a and

~-Actin

expression. To determine whether exogenous miR-333b regulated

c-Myc protein expression, HeLa cells (1 x 106cells/well) cultured in 6-well plates were
transfected with 2.5 Ilg of pSIF, miR-33b, or miR-33bM. Total protein was used for
western blot analysis for the expression of c-Myc, Cyclin E, Gadd45a, ODC, and

~

Actin.

3.2.4. Quantitative real-time PCR (qRT-PCR)
We used TaqMan miRNA and gene expression assays (applied Biosystem inc., Forest
City, CA) to detect the expression level of mature miRNAs and gene mRNA,
respectively (198). U6 RNA and p-Actin mRNA was used for normalization.
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Medulloblastoma D283, Daoy and UW228 cells were treated with lovastatin (0, 0.2, 2, or
10 /lM) and TaqMan qRT-PCR was performed for the expression of miR-33b, MYC
mRNA and SREBFl mRNA. We performed qRT-PCR using total RNA from Daoy cells
treated with vehicle, lovastatin (O.2/lM), mevalonate (lOO/lM) or lovastatinlmevalonate
to determine whether mevalonate inhibits lovastatin-induced up-regulation of miR-33b
and SREBFl mRNA and down-regulation of MYC mRNA. For this, Daoy cells will be
treated with vehicle, lovastatin, mevalonate and lovastatinlmevalonate for 48 hrs. Total
RNA was then extracted using TriZol and TaqMan miRNA and gene expression assay
was used to measure miR-33b/a, SREBF and MYC mRNA expression. To determine
whether orthotopic brains tumors of Daoy and D283 treated with vehicle or lovastatin
had differential levels of miR-33b and miR-9, total RNA was extracted using the TriZol
reagent (Invitrogen, Carlsbad, CA) as per the manufacturer's protocol. A total of 100ng
of total RNA was used for TaqMan miRNA expression assay to measure the expression
level of miR-33b and miR-9. To determine the effect of lovastatin on miR-33b
expression, HeLa cells were treated with lovastatin (0, 0.2, 5 and 10 /lM) and qRT-PCR
was performed 24 and 48hrs later for miR-33b and MYC mRNA expression.
Furthermore, HeLa cells were treated with lovastatin (0.2/lM), Valproic acid (0.2/lM), 5Azacytidine (O.2/lM), lovastatinlvalproic acid or lovastatinl5-azacytidine for 48 hrs. Total
RNA was extracted from treated cells and qRT-PCR performed for MYC mRNA and
miR-33b expression. To determine whether exogenous miR-33b regulated the expression
of c-Myc-mediated miR-9, HeLa cells were transfected with: empty vector or miR-33b;
miRNA inhibitor negative control or anitisense-miR-33b. Total RNA was extracted from
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these cells after 48 hrs and miR-9levels were determined using the miRNA Taqman realtime PCR method as previously described

3.2.5. MTT assay
Daoy cells (3 x 104cells/well) were plated in 96-well plates and treated with 0.2 ~M of
drugs in the NIH clinical collection (NCC) 1 and 2 in triplicate wells. MTT assay was
performed after 48 hrs. Likewise, Daoy and D283 cells were treated in triplicate 96-well
plate with lovastatin (0, 0.2, 2, 10 ~M) for 48 hrs followed by MTT assay. HeLa cells (3
X 104 Cells/ well) were treated with lovastatin (0, 0.2, 2 and lO~M) for 48 hrs followed
by MTT assay. To determine whether epigenetic regulation affects HeLa cells lovastatin
sensitivity, HeLa cells (3 X 104 Cells/ well) in a 96-well plate were treated with vehicle
or lovastatin (O.2~M) alone or with valproic acid (0.2~M) or 5-azacytidine (0.2~M) for
48 hrs. Cell viability of treated cells was compared to normalized vehicle control. HeLa
cells (3x104cells/well) in 96-well plates were transfected with O.l~g of pSIF, miR-33b in
triplicate wells. MTT assay was performed at 2, 4 and 6 days post-transfection as
previously described. Furthermore, HeLa cells were co-transfected with vector control or
miR-33b and pcDNA3.1, pcDNA-MYC-MYC 3'UTR WT or pcDNA-MYC-MYC
3'UTR mut. MTT assay was performed 48 hrs later to determine if exogenous c-Myc
could rescue the miR-33b-induced decrease in cell proliferation.

3.2.6. Apoptosis assay
To determine whether exogenous over-expression of miR-33b increase apoptosis of HeLa
cells, HeLa cells (lx104cells/well) in 12-well plates were transfected with 1 ~g of empty
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vector or miR-33b. Equally, HeLa cells were co-transfected with vector or miR-33b and
pcDNA MYC, pcDNA-MYC 3'UTR WT or mutant constructs in 12 well plates.
Transfected cells were washed with IX PBS and suspended in 500 fll of fresh media at
48, 72 and 144 hrs post transfection. PI (1 flglml) was added and cells incubated in the
dark for 15 mins. Cells were analyzed by flow cytometry (Becton Dickinson, Franklin
Lakes, NJ) within Ihr of staining.

3.2.7. Cell cycle analysis
Also, D283 and Daoy cells were treated with lovastatin (0, 0.2, 2, or 10 flM). The cells
were collected 48 hrs later and flow cytometry was performed and cell cycle analyzed
using FlowJo software (Tree Star Inc., Ashland, OR) as previously described. Likewise
HeLa cells were treated with lovastatin (0, 0.2, 2, 10 or 40 flM) or 0.2 flM of lovastatin,
5-azacytidine, or lovastatinl5-azacytidine for 48 hrs followed by cell cycle analysis. To
determine the effect on cell cycle after over-expression of miR-33b, HeLa cells
(lx104cells/well) in 12-well plates were transfected with Iflglwell pSIF, miR-33b or
miR-33a. For each variable a minimum of 3 samples were quantified.

3.2.8. Transwell cell migration assay
Daoy and D283 cells were treated with 0.2 flM of lovastatin for 48 hrs. The cells were
washed twice in IX PBS after 48 hrs and collected in serum-free EMEM media (Gibco,
Carlsbad, CA). Transwell (Boyden) cell migration assay was then performed as
previously described. Migrated cells were fixed with methanol for 10 mins and stained
with 0.4% crystal violet for 2 hrs. Non-migrated cells on the upper side of the filter were
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removed with a cotton swab, and the filters mounted on microscope glass slides. Images
were captured using a Nikon Eclipse TE300 microscope and a Nikon Plan Fluor lOxO.30
objective. The migrated cells were counted using the ImageJ software. To determine the
effect of exogenous miR-33b on HeLa cells migration, HeLa cells (lx104 cells/well)
were transfected with empty vector, miR-33b, miRNA inhibitor negative control or
antisense miR-33b. Two days after transfection the HeLa cells were collected in fresh
serum-free DMEM and Transwell assay performed.

3.2.9. Tumor formation
All animal experiments were conducted according to a protocol approved by the
University of Louisville Animal Care and Use Committee (IACUC number: 08107). We
used orthotopically medulloblastoma cell-induced mice tumor to determine whether our
In Vitro data is replicable in an animal model. Daoy cells (5 x 106 cells/mice) were
injected subcutaneously into 13 NCRNU-M nude mice. Briefly, the cells were
trypsinized and washed twice in IX PBS. The cells were then resuspended in IX PBS
containing 5% matrigel. The cells were then counted using the Countess meter
(Invitrogen, Carlsbad, CA). A total of 5 X 106 cells in 400 J.lI of media were injected into
each mouse (200 J.lI at each flank of the mice). The animals were monitored for the
formation of tumors. Once tumor reached a volume of 200 J.lm, the mice were separated
into 3 groups (4 animals per treatment group) and the mice were treated three times a
week with 0, 0.2 or I mg/Kg by peritoneal injection. The tumor sizes were measured each
week and volume calculated using the formula; Volume =(rrJ6) (length) (width) (height)
for four weeks after which the mice were sacrificed, tumor sizes measured and tumors
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removed. Also, miR-33b-positive medulloblastoma cell line Daoy and miR-33b-negative
medulloblastoma cell line D283 (1 x 105 cell/mice) were injected orthotopically into the
cerebellum of the 22 mice/cell line as previously described. The mice were housed and
monitored for two weeks for any signs of distress. Two weeks after orthotopic injection,
the mice were treated with vehicle (5 mice) or Imglkg of lovastatin (5 mice) per cell line
by intraperitoneal injection. The mice were sacrificed after 4 weeks of lovastatin
treatment and tumor weight measured relative to whole brain. The tumors were then
incubated in 10% formalin for 3 days, embedded in paraffin and 5 IlM sections cut onto
slides. H&E staining was performed to determine size of D283tumors from mice treated
and Daoy tumors as previously described. Immunohistochemistry (lHC) was performed
using sections from the tumor groups to determine expression level of c-Myc, Sox2,
Cyclin E, PCNA and Caspase 7 as previously described.

3.2.10. EpiTect methy qPCR assay

The EpiTect methyl DNA restriction Kit (Qiagen, Frederick, MD) and the EpiTect
Methyl qPCR Primer Assay for SREBFl (Qiagen, Frederick, MD) were used to
determine the methylation status of the SREBFl promoter following treatment with
lovastatin and lor 5-azacytidine according to the manufacturer's protocol. Briefly, HeLa
cell were treated with vehicle, O.2IlM of lovastatin, 5-azacytidine or lovastatinl 5Azacytidine for 48 hrs. Genomic DNA was extracted using TriZol as per the
manufacturer's instruction and the concentration measured by nanodrop software. The
genomic DNA (1llg) was digested with a methyl sensitive, methyl dependent or methyl
sensitive/dependent enzymes for 6 hrs. The digested DNA was them used as a template
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SBRY (BioRad, Hercules, CA) for qRT-PCR using the SREBFl methyl primer.
Methylation status was determined using the EpiTect methyl DNA methylation PCR data
analysis tool (Qiagen, Frederick, MD).

3.2.11. Statistics
The experimental results were expressed as the mean ± standard deviation of at least 3
independent experiments. Two-tail Student's t-test was performed with p:S0.05 (*)
considered as statistically significant between the samples and their respective controls.

3.3. RESUL TS
3.3.1. Lovastatin up-regulates miR-33b expression and adversely impacts on c-Myc
expression and function in medulloblastoma cells.
We performed a small scale screening assay to identify FDA-approved compounds that
reduce medulloblastoma cell viability and increase miR-33b expression using Daoy, a
medulloblastoma cell line with intact 17pl1.2 and with no gene amplification of MYC
(100, 241). We singled out lovastatin (Fig. 17) as (i) its resulted in inhibition of Daoy
cell proliferation by more than 40% and up-regulated miR-33b expression by 2.8 fold; (ii)
its safety and efficacy has been tested for over thirty years; (iii) statins are reported to
reduce cancer risk (242, 243); and (iv) statins or other cholesterol-lowering approaches
up-regulate miR-33a, the homolog of miR-33b (244-247). MTT cell
proliferation/viability assay was performed after Daoy or D283 cells were treated with
increasing concentration of Lovastatin. The decrease in cell proliferation was lovastatin
dose-dependent in Daoy but did not affect the proliferation of D283 cells (Fig. 18).
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Fig. 17: Lovastatin most significantly resulted in reduced Daoy cell proliferation
and up-regulation of miR-33. A small scale screening assay to identify FDAapproved compounds that reduce medulloblastoma Daoy cell proliferation and
increase miR-33 b expression.
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A qRT-PCR assay showed that in Daoy cells, lovastatin induced miR-33b and SREBFl
expression in a dose-dependent manner, while MYC mRNA was down-regulated (Fig.
19A). Yet there was no significant change in MYC mRNA levels upon lovastatin
treatment in D283 cells (Fig. 19C). We tested the promoter of the human SREBF1-miR33b gene and found that lovastatin increased the promoter activities (Fig. 20A). In

addition, mevalonate inhibited the induction of miR-33b and SREBFl and MYC mRNA
down-regulation by lovastatin in Daoy cells (Fig. 20C), suggesting lovastatin activates
miR-33b through the cholesterol biosynthetic pathway. In D283 cells, mevalonate did
not affect the expression of MYC mRNA (Fig. 20B). Using other statins, we found that
miR-33b expression was also increased but in a less significant manner compared to
lovastatin (Fig. 21).
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Correspondingly, lovastatin caused reduction in c-Myc, Cyclin E and ODC protein levels
and up-regulation of Gadd45a in Daoy (Fig. 22A) but not in D283 cells (Fig. 22B). We
also treated UW228 (another cell line with an intact 17p 11.2) with lovastatin and found
there was a significant induction of miR-33b and SREBF1, and a decrease in MYC
mRNA expression in UW228 cells (Fig. 19B). Equally, protein levels of c-Myc and its
transcriptional targets Cyclin E and ODC are down-regulated in a dose-dependent
manner by lovastatin in UW228 cells, while Gadd45a was up-regulated (Fig. 22A) This
is in line with a previous report that Daoy and UW228 are more sensitive to lovastatin
than D283 (248). Cell cycle analyses demonstrated that more Daoy but not D283 cells
had delay G 1 phase progression upon lovastatin treatment (Fig. 23). Lovastatin resulted
in decreased levels of miR-9 (Fig. 24A) and a corresponding reduction in cell migration
of Daoy cells (Fig. 24B) but did not affect miR-9 (Fig. 24A) levels or cell migration of
D283 cells (Fig. 25B).
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3.3.2. Lovastatin decrease tumor growth of miR-33b-postive medulloblastoma Daoy,
but not D283, cells in immunodeficient nu/nu mice
We treated mice subcutaneously injected with Daoy cells to form xenografts and found
either 1.0 mglkg or 0.2 mglkg of lovastatin treatment resulted in smaller tumor sizes (Fig.
25A) and lower c-Myc expression (Fig. 26D). We then tested whether lovastatin reduces
the brain tumor burden in an orthotopic model, which requires testing compounds to
penetrate the blood-brain barrier (BBB), a separation of circulating blood and
cerebrospinal fluid in the central nervous system. Lovastatin is lipophilic and is able to
penetrate the BBB, and this comes with some side effects such as sleep disturbances
(249,250). We inoculated Daoy or D283 cells into the brain of immunodeficient mice
and treated them with 1.0 mglkg of lovastatin. At the end of regimen (4 wks), all Daoybearing mice in the control group became moribund or paralyzed; yet mice in the
lovastatin group appeared physically normal. We found that Daoy-xenografted mice
treated with lovastatin had less tumor expansion in the ventricles; and strikingly, tumor
invasion into the surrounding cerebellar tissues was completely blocked (Fig. 25B). In
contrast, D283 xenograft neither invaded surrounding tissues nor responded to lovastatin
treatment (Fig.25B). Lovastatin treatment led to miR-33b up-regulation (Fig. 26B) and
lowered expression of miR-9 (Fig. 26A), c-Myc, and Cyclin E in tumors of Daoy (Fig.
26C) but not in that of D283 cells (Fig. 26A & C). There was no statistically significant
change in the percentage of PCNA-positive cells in control tumors versus treated Daoy
tumors (Fig. 26C), suggesting cell cycle arrest rather than apoptosis is a likely cause for
attenuated tumor growth in vivo.
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lovastatin (left). Average surface area from tumors in vehicle or lovastatin
treated group (Right)
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3.3.3. The methylation inhibitor 5-azacytidine sensitize HeLa cells to lovastatininduced inhibition of cell growth
There was no change in proliferation of HeLa cell treated with increasing concentration
of lovastatin (0, 0.2, 2, or 10 /lM), except at the high concentration of 40 /lM (Fig. 27 A),
a concentration used to synchronize HeLa cells at G 1 phase of the cell cycle (251). QRTPCR shows that in HeLa cells, lovastatin did not affect the levels of miR-33b and MYC
mRNA (Fig. 27B & C). Correspondingly, lovastatin did not affect the protein levels of cMyc and its target gene Cyclin E, ODC and Gadd45a (Fig. 27D). Cell cycle analysis
revealed that at a concentration up to 10 /lM there was no change in cell cycle
progression (Fig. 28B). Using FDA-approved drugs that were found to up-regulate miR33b in Daoy cells, qRT-PCR using RNA from HeLa cells treated with 0.2 /lM of these
drugs did not significantly affect on miR-33b expression (Fig. 28A).
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HeLa cell proliferation was significantly reduced in response to valproic/lovastatin acid
or 5-azacytidine/lovastatin treatments compared to lovastatin, valproic acid, 5-azacytidine
or vehicle treatment alone (Fig 29A). The reduced proliferation corresponded with upregulation of miR-33b expression and decreased MYC mRNA (Fig 29B & C).
Furthermore, c-Myc, Cyclin E and ODC protein expression levels were down-regulated,
and Gadd45a expression was up-regulated in HeLa cells treated with 5azacytidinellovastatin (Fig. 29D). Cell cycle analysis show that 5-azacytidine/lovastatin
increased Gl cell cycle arrest (Fig. 30B). A methylation assay demonstrates that 5azacytidine decrease the methylation status of the SREBF1-miR-33b promoter to levels
comparable to lovastatin sensitive Daoy cells (Fig. 30A). These results suggest that
methylation on the SREBF1-miR-33b promoter might contribute to reduced lovastatin
sensitivity in HeLa cells.
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3.3.4. miR-33b down-regulates endogenous c-Myc expression and adversely affect its
function in HeLa cells
Next, we determined the expression of c-Myc and its transactivational targets in HeLa
cells following miR-33b over-expression. We found down-regulation of c-Myc, Cyclin
E, ODC (Fig. 31A), and miR-9 (Fig. 33A), a miRNA regulated by c-Myc (252) and upregulation of Gadd45a (Fig. 31A) by miR-33b but not by miR-33bM in HeLa cells,
similar to that in 293T cells. Additionally, MYC rnRNA levels were reduced in response
to miR-33b over-expression (Fig. 31B).
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As cyclin E expression is required for G 1-S phase transition during cell cycle, we
perfonned cell cycle analyses using flow cytometry. As shown in Fig. 32A, miR-33b,
but not miR-33bM or the control resulted in more cells arrested at the G1 phase.
Moreover, as c-Myc is reported to promote cell proliferation, and cell migration (100,
211-213,215), we perfonned MTT, and Transwell assays to detennine whether these cMyc functions in HeLa cells were compromised by miR-33b. As expected, cells with
miR-33b over-expression have a significant reduction in cell proliferation (Fig. 32B), and
cell migration (Fig. 33B), indicating miR-33b down-regulate endogenous c-Myc
expression and adversely affect c-Myc function in HeLa cells. We also inhibited miR33b expression using modified antisense oligonucleotides against miR-33b (Anti-miR33b) and found that the expression of c-Myc was up-regulated, so did cyclin E (Fig.
31C), amnd miR-9 (Fig. 33A) whereas Gadd45a was down-regulated (Fig. 31C). Cell
migration was increased when miR-33b was inhibited (Fig. 33B). We next detennine
whether exogenous expressed c-Myc could rescue apoptosis induced by miR-33b. We
co-transfected cells with a c-Myc-expressing construct with a WT or a mutant 3'UTR and
miR-33b. Flow cytometry results show that exogenous c-Myc, with the mutant UTR
(which is not targeted by miR-33b) but not that with WT, is able to rescue apoptosis
caused by miR-33b over-expression (Fig. 34). These results demonstrate that miR-33b
overexpression negatively affects HeLa cells c-Myc-mediated functions.
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3.4. DISCUSSION
Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor,
blocks the mevalonate pathway, decreasing cholesterol biosynthesis as well as the
production of non-steroidal mevalonate derivatives (253). Lovastatin has profound
cellular effects, including inhibition of proliferation and induction of apoptosis of cancer
cells (254, 255), including medulloblastoma cells (256), and has been used as a potential
anticancer drug in clinical studies (257, 258). In this study, we show that lovastatin can
be used against tumors through modulation of an miRNA targeting c-Myc. As described
earlier, medulloblastoma show over-expression of c-Myc in 64% of cases but only 1015% show MYC genomic amplification. The second major characteristic is that a subset
(-17%) has a major breakpoint on chromosome 17p11.2, which results in chromosomal
deletion at the breakpoint (259). One of the genes found in this deleted region is

SREBF1-miR-33b, which is important in lipid metabolism and harbors miR-33b on
intron 17. Interestingly, medulloblastoma cells that have this chromosome breakpoint
show lower sensitivity to lovastatin treatment (256). We show that lovastatin treatment of
medulloblastoma cell line Daoy results in a significant reduction in cell proliferation, an
effect not observed in D283 cells. Lovastatin-induced inhibition of Daoy cell
proliferation correlated with an increase in miR-33b expression as well as a downregulation of c-Myc expression. Treatment of mice with lovastatin resulted in a
significant reduction of Daoy tumor growth. Concordantly, the tumors expressed lower
levels of miR-9, c-Myc and Cyclin E. This, to our knowledge, is the first evidence of
pharmaceutical modulation of c-Myc via a miRNA, and provides a new approach to
cancer therapy by targeting miRNA with repurposed drugs.
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Sensitivity to lovastatin is cell-type specific (260). In the case of HeLa cells, lovastatin
treatment has no effect on miR-33b expression. We hypothesize that epigenetic silencing
of the SREBF1 gene promoter is responsible for the reduced lovastatin sensitivity. In
mammals, the best understood epigenetic modification of DNA is post-replicative
methylation of the C5 position of cytosine residues in CpG dinucleotides. We did find
the SREBF1 promoter was significantly methylated in HeLa cells, but not in Daoy cells.
5-Azacytine is an FDA-approved antitumor drug that acts as a methyltransferase
inhibitor, that prevents epigenetic gene silencing (261,262). When HeLa cells were
treated with 5-Azacytidine along with lovastatin, miR-333b was up-regulated and MYC
was down-regulated. This was accompanied with decreased methylation of the SREBF1
promoter, as well as suppression of c-Myc-mediated cell proliferation, cell migration and
cell cycle progression.

In summary, we have documented here that lovastatin represses the oncogenic activities
of c-Myc through activation of miR-33b transcription. Furthermore, lovastatin sensitivity
may be augmented in cells that are resistant with the methylase inhibitor 5-Azacytidine.
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CHAPTER 4

CONCLUDING REMARKS
Tumor development is hallmarked by a variety of genetic and epigenetic alterations in
protein-coding genes and small non-coding RNA genes. MYC is a major oncogene
encoding the transcription factor c-Myc. miRNAs are a diverse family of small RNAs
that regulate the stability and translational efficiency of partially complementary target
mRNAs (263, 264). By regulating specific oncogenes or tumor-suppressor molecules,
these small RNAs may have profound effects in tumor development (265). A few target
genes have been validated for some miRNAs, and each individual miRNA can target
mUltiple genes and participate in diverse physiological or pathological functions. In this
study we aimed at elucidating miRNAs that target MYC. Using an array of molecular
techniques including reporter assays, western blot analysis, cell cycle analysis, cell
migration and cell proliferation assays, we showed that MYC is a miR-33b target gene.

Medulloblastoma is characterized by an over-expression of c-Myc. While 64% of
medulloblastomas have over-expression of c-Myc, yet only 5-15% of medulloblastomas
show MYC gene amplification (96, 266). Myc over-expression is a biomarker associated
with poor prognosis of medulloblastoma, along with chromosome 17p breakpoint
abnormalities. Interestingly, Myc over-expression without genomic amplification is
mostly observed in the more aggressive and metastatic anaplastic subtype of
medulloblastoma (96,267-269). The human miR-33b gene is located in intron 17 of the
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SREBFJ-miR-33b gene and this genomic locus, 17pl1.2, is frequently lost in

medulloblastoma (44, 228, 270). Breakpoints on chromosome 17p, similar to that in
Smith-Magenis syndrome, present in medulloblastoma either leads to complete deletion
of this chromosomal regions or it is translocated to chromosome 17 q thereby forming an
isochromosome i17q (227). We have determined that miR-33b targets MYC and
adversely affects its biological functions in medulloblastoma. Therefore the loss of miR33b expression could in part explain the over-expression of c-Myc in a subset of
medulloblastoma. Various functional assays were used to show that re-introduction of
miR-33b in anaplastic medulloblastoma D283 cells negatively affects medulloblastoma
tumorigenic proporties by reducing cell proliferation, cell migration, and cell cycle
progression. Using neurosphere assays, immucytochemistry and qRT-PCR, we show that
miR-33b re-introduction results in reduction of neurospheres formed by medulloblastoma
D283 cells and down-regulation of stem cell markers such as CD133, SOX2, Musashi
andMEKL.

We decided to use drug repurposing to elevate miR-33b and inhibit c-Myc. We
performed a small scale screening of FDA-approved drugs and found that lovastatin
inhibits cell growth and increases miR-33b levels in Daoy cells. Lovastatin downregulated c-Myc expression and led to Gl arrest in the miR-33b-positive Daoy cells, but
not in the miR-33b-null D283 cells. The change in miR-33b expression upon lovastatin
treatment reciprocally corresponded with c-Myc expression. These results suggest that
lovastatin acts in part as an activator of miR-33b expression, which, in tum, decreases
cellular proliferation through suppression of the MYC gene. We then tested whether
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lovastatin reduces the brain tumor burden in an orthotopic model, which requires the
testing compounds to penetrate the blood-brain barrier (BBB), a separation of circulating
blood and cerebrospinal fluid in the central nervous system. Lovastatin is lipophilic and
is able to penetrate the BBB (250,271). We found that lovastatin slows the growth of
tumors inoculated with Daoy, but not that with D283 (a miR-33b-negative cell line).
This suggests a therapeutic option against medullablastoma with lovastatin using miR33b as a biomarker.

However, not all cell lines are responsive to lovastatin, one of which is HeLa. This
could be due to hypermethylation of the promoter to SREBF1, the host gene for miR-33b
(272). We did find that this promoter is methylated at a higher level in HeLa compared
with Daoy cells. When treated with a methylase inhibitor, 5-azacytidine, HeLa cells
became sensitive to lovastatin, along with reduced methylation of the promoter. In
addition, increased sensitivity to lovastatin correlated with up-regulation of miR-33b and
down-regulation of c-Myc expression in HeLa cells treated with 5-azacytindine. These
results suggest that DNA hypermethylation of the SREBFl promoter is the underline
mechanism of 10vastatin insensitivity in HeLa cells.

Taken together, this study has: (i) identified that miR-33b targets MYC; (ii) suggested that
miR-33b loss may contribute to c-Myc over-expression in some medulloblastomas; (iii)
revealed that 10vastatin is an attractive chemotherapeutic agent against medulloblastoma
with a native miR-33b gene; (iv) shown that the resistance of 10vastatin in HeLa cells is
likely a result of epigenetic inactivation of the SREBFl ~miR-33b gene; and (v) presented
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a highly promising therapeutic option, using drug repurposing and a miRNA as a
biomarker, against cancers that over-express c-Myc.
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Fig. 35: Proposed schematic of lovastatin induce inhibition of medulloblastoma cell
growth. Lovastatin decreases medulloblastoma cell growth by positively modulating
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Appendix II
Abbr -

Full

3 'UTR - 3' Untranslated Region
APC - Polyposis Coli
AR -Average Risk
bHLHZip - Basic Helix-Loop-Helix Leucine Zipper
CDC25A - Cell Division Cycle 25A
CDK - Cyclin Dependent Kinase
CGH - Comparative Genomic Hybridization
CKla - Casein Kinase la
CLL - Chronic Lymphocytic leukemia
CNS - Central Nervous System
CRT - Conformal Radiation Therapy
CSC - Cancer Stem Cell
CSRT - Craniospinal Radiatherapy
CT - CAT scan
Dsh - Dishevelled
E2F 112 - E2 promoter binding Factor 112
EGFR -Epidermal Growth Factor Receptor
EGL - External granular layer
ES - Embryonic Stem cells
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FBW7 - F-box and WD repeat domain containing 7
GFP - Greem Fluorescent Protein
GSK-3p - Glycogen Synthase Kinase -3P
HAT - Histone acetyl Transferase
HGF - Hepatocyte Growth Factor
HGMA2 - high mobility group AT-hook 2
HIF-l - Hypoxia-Inducible Factor!
HR - High Risk
HSC - haematopoietic Stem cell
IGFR - Insulin-like Growth Factor Receptor
IQ -Intelligence Quotient
LAIC - Large/anaplastic medulloblastoma
LDL - Low density lipoprotein
LR-Lowrisk
LRP - LDL Receptor-related Protein
MB -Myc-Box
MBEN -Medulloblastoma with extensive nodularity
miRNA - MicroRNA
MRI - Magnetic resonance Imaging
Mut-Mutant
ncRNA - Non-coding RNA
NSC - Neural Stem Cell
nt

- Nucleotide

140

ODC - Ornithine Decarboxylase
PDCD4 - programmed Cell Death 4
PDGFR - Platelet-derived growth Factor receptor
PI3K - Phosphatidylinositol-3-kinase
PNET - Primitive neuroectodennal tumor
PNK -Polynucleotide Kinase
RB - Retinoblastoma
RFP (mKate) - Red Fluorescent Protein
RISC - RNA-Induced Silencing Complex
ROS -Reactive Oxygen Species
RTK - Receptor Tyrosine Kinase
SC - Stem cell
Shh - Sonic Hedgehog
SREBFl - Sterol Regulatory Element Binding Transcription Factor 1
TAD - Transactivation domain
TcfILef - T-cell factor/lef
TGFB - Transfonning Growth Factor B
TIC - Tumor Initiating Cell
TRK - Tyrosine Kinase
VEGF - Vascular endothelial Growth Factor
WHO - World Health Organization
Wnt - wingless
WT -Wild type
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ZEB - Zinc finger E-box binding Factor
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